Hauptseite | Die Praxis | Dr. Ivan Foeldvari | Was ist Rheuma? | Die Elterninitiative | Kontakt | Impressum | Links

Der Arzt - Wissenschaftliche Veröffentlichungen  (Stand: 04/2013)

Dr. Ivan Foeldvari


Doktorarbeit
Orginalberichte
Übersichtsarbeiten
Beiträge zu Fachbüchern
Einladungen zu Vorträgen
Vorträge auf Kongressen
Letters
Poster-Präsentationen mit veröffentlichten Abstracts
Abstracts-Präsentationen


Doktorarbeit:
Immunmodulationstherapie. Doktorvater: P. Gergely, I. Medizinische Klinik, Semmelweiss Universität, Budapest.

nach oben

Orginalberichte:

  1. S. Lederman, J.A. DeMartino, B.L. Daugherty, I. Foeldvari, M.J. Yellin, A.M. Cleary, N. Berkowitz, I. Lowy, N.S. Braunstein, G.E. Mark and L. Chess: A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol.Immunol.1991; 28 (11): 1171-1181. – Impact factor- 2,98
  2. I. Foeldvari, R.A. Cairns, R.E. Petty, D.A. Cabral: An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: A case report. Clin Exp Rheumatol 1995;13 : 525-8.- – Impact factor- 2,4
  3. I. Foeldvari, E. Waida, A. K. Junker: Systemic capillary leak syndrome in a child. A case report. J Pediatrics 1995; 127: 739-41. – Impact factor- 4,042
  4. I. Foeldvari, A. Wuesthof: Delayed diagnosis of juvenile rheumatoid arthritis in a girl with Turner Syndrome. Clin Exp Rheum 1997,15:701-3. - Impact factor- 2,4
  5. I. Foeldvari, M. Schmitz: Rapid development of a severe osteoarthritis associated with osteoid osteoma in a young girl. Clinical Rheumatology 1998, 17:534-7. – Impact factor- 1,283
  6. I. Foeldvari, M. Birdi: Validation of the proposed Durban classification criteria for juvenile idiopathic arthritis in the patient population of the pediatric rheumatology clinic in Hamburg, Germany. J Rheumatol 2000, 27:1069-72. – Impact factor- 3,551
  7. I. Foeldvari, M. Zhavania, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, H Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian: Favourable outcome in 135 children with juvenile systemic sclerosis (jSSc): Results of a multinational survey. Rheumatology 2000,39:556-9. – Impact factor- 4,171
  8. P.H. Hoeger, N. Veelken, I. Foeldvari: Neonatal onset of rash in Still´s disease. Journal of Pediatrics 2000; 137:128-31. – Impact factor- 4,042
  9. I. Foeldvari, A. Thon, R. Burgos-Vargas: Studienergebnisse zum COX-2-Hemmer Meloxicam. Rheuma aktuell 2000, 4/00:14-16. – Impact factor- NN
  10. J. M. Maerker, A. Harm, I. Foeldvari, P.H. Hoeger: Naproxen-induzierte Pseudoporphyrie. Hautarzt, 2001,52:1026-9. – Impact factor- 0,451
  11. I.Foeldvari, N. Ruperto, F. Dressler, R. Häfner, R.M. Küster, H.Michels, K.Minden, C. Schauer-Petrowskaja, M.Bullinger, J.M.Landgraf, H.I. Huppertz, for the Paediatric Rheumatology International Trials Organisation (PRINTO): The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001, 19 Suppl 23:S 71- S 75. – Impact factor- 2,4
  12. I. Foeldvari, R. Burgos-Vargas, A. Thon,D.Tuerck: High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 1079-83. – Impact factor- 3,551
  13. I. Foeldvari, C. Thiel, M. Eiselt, J. Weil: Juvenile spondyloarthritis and severe cardiac involvement. In a female paient. J. Rheumatol 2003, 30: 1087-9. – Impact factor- 3,551
  14. K. Meyer, I. Foeldvari, R.M. Küster, L. Huck, B. Kahl-Nieke: Das Kiefergelenk bei juveniler idiopathischer Arthritis. Zahnärztliche Welt Rundschau. Das deutsche Zahnärzteblatt 2003, 112: 64- 74. – Impact factor- NN
  15. I. Foeldvari. Pediatric Rheumatology in Germany: A new model to set up a pediatric rheumatology service in Germany. Pediatric Rheumatology online Journal 2004,Vol 2. No.2. – Impact factor- 1,74
  16. R. Burgos Vargas, I. Foeldvari, A. Thon.,R. Linke, D Tuerck: Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. Journal of Clinical Pharmacology 2004; 44: 866-872.- Impact factor- 3,59
  17. G. Horneff, H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, HJ. Girchick, T. Hospach, HI. Huppertz,R. Keitzer, RM: Küster, H. Michels, D. Moebius, B. Rogalski, A. Thon for the Pediatric Rheumatologiy Collaborative Group. The German Etnercept registry for treatment of juvenile idiopathic arthritis. Annals of Rheumatic Diseases 2004; 63: 1638-44. Impact factor-9,082
  18. Nicolino Ruperto, 2Nina Kuzmina, 3Evgueni D. Pachanov, 4Ynessa Shachbazian, 5Richard Mouy, 6Rik Joos, 7Francesco Zulian, 8Rudolf Schwarz, 9Valeria Artamonova, 10Walter Emminger, 1Marcia Bandeira, 1Antonella Buoncompagni, 11Ivan Foeldvari, 12Fernanda Falcini, 13Eileen Baildam, 14Isabelle Kone-Paut, 15Mariolina Alessio, 16Valeria Gerloni, 17Alessandro Lenhardt, 1Alberto Martini, for the Paediatric Rheumatology International Trials Organisation (PRINTO), 18Gertraud Hanft, 18Ralf Sigmund, 18Stefan Simianer. A randomized, double-blind clinical trial of two doses of meloxicam compared to naproxen in juvenile idiopathic arthritis: short and long term efficacy and safety results. Arthritis Rheum 2005;52:563-572. Impact factor- 8,435
  19. I Foeldvari , A Wierk. Methotrexat is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J.Rheumatology 2005; 32: 362-366. Impact factor- 3,551
  20. D. E. Furst, D Khanna,M Mattucci-Cerinic, A Sillman, P.A. Merkel and I Foeldvari. Report of the Scleroderma - Developing measures of response. J Rheumatol 2005. 32: 2477-80. Impact factor – 3,551
  21. I. Foeldvari, A. Wierk: Healthy children have a significantly increased skin score assessed with the modified rodnan skin score. Rheumatology 2006, 45: 76-78. Impact factor 4,171
  22. Francesco Zulian, Balu H Athreya, Ronald Laxer, Audrey M Nelson, Sheila Knupp Feitosa de Oliveira, Marilynn G Punaro, Ruben Cuttica, Gloria C Higgins, Lisette W.A. Van Suijlekom-Smit, Terry L Moore, Carol Lindsley, Julia Garcia Consuegra, Maria Odete Esteves Hilário, Loredana Lepore, Clovis A Silva, Claudia Machado, Stella M Garay, Yosef Uziel, Giorgia Martini, Ivan Foeldvari, Andrea Peserico, Patricia Woo and John Harper, for the Juvenile Scleroderma Working Group of the Pediatric: Juvenile Localized Scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006, 45: 614-620. Impact factor- 4,171
  23. D.A. Cabral, R.M. Laxer, J. Schrader , S. Turvey, A. Stevens, R.S.M. Yeung, H.E. Forster, H. Emery. J. Premdiville, L.B. Tucker, I. Foeldvari, D.D. Sherry, A.B. Klinkhoff, C.A. Wallace, K. Houghton. Old challenges and new directions in pediatric rheumatology. J Rheumatol 2006, 33: 173-84. Impact factor- 3,551
  24. C. Boschan, O. Witt, L. Schweigerer, P. Lohse, I. Foeldvari, H. Zappel. Neonatal- onset multisystem inflammatory disease (NOMID): new mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. American Journalo of Medical Genteics 2006;140 A: 883-6. Impact factor- 2,505
  25. O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, L. Rubin, D. Furst. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis Rheumatology 2006, 45: 1455-7. Impact factor- 4,171
  26. Giorgia Martini1, Ivan Foeldvari2, Ricardo Russo3, Ruben Cuttica4, Anne Eberhard5, Angelo Ravelli6, Thomas H Lehman7, Sheila Knupp Feitosa de Oliveira8, Gordana Susic9, GA Lyskina10, Dana Nemcova11, Robert Sundel12, Fernanda Falcini13, Herman Girschick14, Ana Paula Lotito15, Antonella Buoncompagni6, Flavio Sztajnbok16, S Al-Mayouf17, Orban Ilonka18, Clodoveo Ferri19, Balu H Athreya20, Patricia Woo21 and Francesco Zulian1 for the Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Systemic Sclerosis in childhood: clinical and immunological features of 153 patients. An international database Arthritis and Rheumatism 2006, 54:3971-8. Impact factor- 8,435
  27. K. Minden, M. Niewerth, G. Ganser, I. Foeldvari, A. Thon, A Zink : Die Kerndokumentation rheumakranker Kinder und Jugendlicher. Kinder- und Jugenmedizin 2006;6: 312-7. Impact factor- NN
  28. Sheila Oliveira,1 Angelo Ravelli,1 Angela Pistorio,2 Esteban Castell,1 Clara Malattia,3 Anne Marie Prieur,4 Claudia Saad-Magalhães,5 Kevin J. Murray,6 Sang-Cheol Bae,7 Rik Joos,8 Ivan Foeldvari,9 Carolina Duarte,10 Nico Wulffraat,11 Pekka Lahdenne,12 Pavla Dolezalova,13 Jaime de Inocencio,14 Polyxeni Pratsidou-Gertsi,15 Michael Hofer,16 Irina Nikishina,17 Huri Ozdogan,18 Phil Hashkes,19 Alberto Martini,20 Nicolino Ruperto,1 for the Pediatric Rheumatology International Trials Organisation (PRINTO). Proxy-reported Health related Quality of Life of patients with juvenile idiopathic arthritis. The PRINTO multinational quality of life cohort. Arthritis and Rheumatism 2007, 57:35-43. Impact factor- 8,435
  29. I. Foeldvari, S. Nielson, K. Rothe, J. Kümmerle-Deschner, G. Espada, G. Horneff, B. Blanca, .A. Oliviere, C.le Blanc, M. Fischbach, S. Grayay, M. Henrickson, M.M. Katsikas, K.O´Neil, J.P. Whelan, A. Wierk, T. Saurenmann. Tumor Necrosis Factor- alfa in the treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: Results of a multinational survey. Journal of Rheumatology 2007, 34: 1146-50. Impact factor- 3,551
  30. Francesco Zulian,1 Patricia Woo,2 Balu H Athreya3 Ronald M Laxer4, Thomas A. Medsger Jr,5 Thomas H Lehman,6 Marco Matucci Cerinic,7 Giorgia Martini,1 Angelo Ravelli,8 Ricardo Russo,9 Ruben Cuttica,10 Sheila Knupp Feitosa de Oliveira,11 Christofer Denton,12 Franco Cozzi,13 Ivan Foeldvari,14 Nicolino Ruperto8 for the Pediatric Rheumatology European Society (PRES). The Pediatric Rheumatology European Society/American Collerge of Rheumatology/ European League Against Rheumatism Provisional classification criteria for systemic sclerosis. Arthritis and Rheumatism 2007: 57:203-212. Impact factor- 8,435
  31. Daniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, Philip Clements, Virginia Steen, Janet Pope, Peter Merkel, Ivan Foeldvari, James Seibold, David Pittrow, Vibeke Strand, Richard Polisson Systemic Sclerosis – Continuing Progress in Developing Clinical Measures of Response, OMERACT 2006. J. Rheumatol 2007;34:1994-1200. Impact factor- 3,551
  32. U.A. Walker, A. Tyndall, L. Czirjak,….. I. Foeldvari 98, ….. Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR scleroderma trials an research group database. Ann Rheum Dis 2007, 66: 754-63. Impact factor- 9,082
  33. N Ruperto, A Ravelli, A Pistorio, V. Ferriani, PISTORIO, I Calvo, G Ganser, J Brunner, G Dannecker, CA Silva , V Stanevicha, R ten Cate, L W. A. Van Suijlekom-Smit, O Voygioyka, M Fischabach, I Foeldvari, et al. For the Peadiatrich Rheumatology Internation Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) . The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease Activity Core Set for the Evaluation of Response to Therapy in Juvenile Dermatomyositis: A Prospective Validation Study. Arthritis Rheumatism 2008, 59: 4-13. Impact factor- 8,435
  34. Oliver Distler1, Frank Behrens2, David Pittrow3, Doerte Huscher4, Christopher P Denton5, Ivan Foeldvari6, Marc Humbert7, Marco Matucci-Cerinic8, Peter Nash9, Christian Opitz10, Lew Rubin11, Jim Seibold12 and Daniel E. Furst13 for the other coauthors of the EPOSS-OMERACT group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphi consensus study with cluster analysis . Arthritis Care & Research, 2008; 59:867-75. Impact factor- 4,749
  35. Daniel J. Lovell, M.D., M.P.H., Nicolino Ruperto, M.D., M.P.H., Steven Goodman, M.D., Andreas Reiff, M.D., Lawrence Jung, M.D., Katerina Jarosova, M.U.Dr., Dana Nemcova, M.D., Anne-Marie Prieur, M.D., Christy Sandborg, M.D., John Bohnsack, M.D., Dirk Elewant, M.D., Ivan Foeldvari, M.D., Valeria Gerloni, M.D., Jozef Rovensky, M.D., Ph.D., Kirsten Minden, M.D., R. Vehe, M.D., L. Wagner Weiner, M.D., Gerd Horneff, M.D., Hans-Iko Kuppertz, M.D., G. N. Olson, M.D., John R. Medich, Ph.D., Roberto Carcereri-De-Prati, M.D., Melissa J. McIlraith, Ph.D., Edward H. Giannini, M.Sc., Dr.P.H., and Alberto Martini, M.D., for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Pediatric Rheumatology International Trials Organisation (PRINTO). Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. NEJM 2008; 359:810-820. Impact factor- 8,41
  36. Khanna D, Lowell DJ, Ginannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denot CP, Mayes MD, Steen VD, Varga J, Furst DE for the Scleroderma Clinical Trial Consortium coauthors…. Foeldvari I……. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703-9. Impact factor- 8,435
  37. N. Hunzelmann 1, E. Genth2, T. Krieg1, W. Lehmacher3, I. Melchers4, M. Meurer5, P. Moinzadeh1, U. Müller-Ladner 6, C. Pfeiffer5, G. Riemekasten7, E. Schulze-Lohoff 8, C. Sunderkoetter9, M. Weber8, M. Worm 10, P. Klaus10, A. Rubbert11, K. Steinbrink12, B. Grundt12, R. Hein13, K. ScharffetterKochanek 14, R. Hinrichs14, K. Walker14, R.-M. Szeimies15, S. Karrer15,A.Müller16, C. Seitz17, E. Schmidt 17, P. Lehmann18, I. Foeldvari19, F. Reichenberger20, W. L. Gross21, A. Kuhn22, M. Haust22, K. Reich 23,M.Böhm9, P. Saar16, G. Fierlbeck24,I.Kötter25, H.-M. Lorenz26, N. Blank26, K. Gra ¨ fenstein 27, A. Juche27, E. Aberer28, G. Bali28, C. Fiehn29, R. Stadler30 and V. Bartels30. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47: 1185-1192. Impact factor- 4,171
  38. Horneff, G. De Bock, F. Foeldvari, I. Girschick, H. J., Michels, H. Moebius, D. Schmeling, H. : Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68:519-25. Imapct factor 9,087
  39. Kowal-Bielecka O (1) Landewé R (2), Avouac J (3), (3), Chwiesko S (1), Miniati I (4), Czirjak L (5), Clements P (6), Denton C (7), Farge D (8), Fligelstone K (9), Földvari I (10), Furst DE (6), Müller-Ladner U (11), Seibold J (12), Silver RM (13), Takehara K (14), Garay Toth B (15), Tyndall A (16), Valentini G (17), van den Hoogen F (18), Wigley F (19), Zulian F (20), Matucci-Cerinic M (4) and EUSTAR coauthors*. EULAR/EUSTAR Recommendations for the Treatment of Systemic Sclerosis. Ann Rheum Dis 2009, 68:620-628. Impact factor- 9,087
  40. Ivan FOELDVARI, ILONA S. SZER, LAWRENCE S. ZEMEL, DANIEL J. LOVELL, EDWARD H. GIANNINI, JEFFREY L. ROBBINS, CHRISTINE R. WEST, GINA STEIDLE, SRIRAM KRISHNASWAMI, and BRADLEY J. BLOOM. A Prospective Study Comparing Celecoxib With Naproxen in Children With Juvenile Rheumatoid Arthritis. J Rheumatol 2009, 36: 174-182. Impact factor- 3,551
  41. Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foeldvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM; Takehara K, Garay Toth B, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M and EUSTAR coauthors. European League against Rheumatism (EULAR) Scleroderma Trial and Research Group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of the systemic literature research. Ann Rheum Dis 2009,68: 629- 634. Impact factor- 9,087
  42. Horneff G , Ebert A , Fitter S , Minden K , Foeldvari I , Kümmerle-Deschner J , Thon A , Girschick HJ , Weller F , Huppertz HI. Safety and efficacy of once weekly Etanercept 0.8 mg/kg in a multicentre 12 weeks trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009;48:916-919. Impact factor- 4,17
  43. Horneff G De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, for the the German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis: preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-25. Impact factor- 9,087
  44. Dinesh Khanna*, Oliver Distler*, F Behrens , Philip Clements, Christopher Denton, Edward Giannini, Doerte Huscher , Ivan Foeldvari , Daniel Lovell, Marco Matucci-Cerenic, Maureen Mayes, Peter Merkel, Peter Nash, C Opitz, David Pittrow, Lewis Rubin, James Seibold, Virginia Steen, Vibeke Srand, Peter Tugwell, John Varga, Angela Zink and Daniel E.Furst** for the investigators in CRISS and EPOSS(*co-first authors;**Senior author; all other cited authors in alphabetical order). Measures of Response in Clinical Trials of Systemic Sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in PAH Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009,36:2356-61. Impact factor- 3,551
  45. Jérôme Avouac* (1), Otylia Kowal-Bielecka* (2), David Pittrow (3), Doerte Huscher (4), Frank Behrens (5), Christopher P Denton (6), Ivan Foeldvari (7), Marc Humbert (8), Marco Matucci-Cerinic (9), Peter Nash (10), Christian F. Opitz (11), Lewis J. Rubin (12), James R. Seibold (13), Oliver Distler * (14) and Daniel E. Furst * (15) for the EPOSS group *contributed equally. Validation of the six-minute walk test according to the OMERACT filter: a systematic literature review. Ann Rheum Dis 2010, 69: 1360-3. Impact factor- 9,087
  46. Nicolino Ruperto, M.D., M.P.H.; Daniel J. Lovell, M.D., M.P.H.; Ruben Cuttica, M.D.; Patricia Woo, M.D., Prof.; Silvia Meiorin, M.D.; Carrie Wouters, M.D. PhD.; Earl D. Silverman, M.D.; Zsolt Balogh, M.D.; Michael Henrickson, M.D.; Joyce Davidson, M.D.; Ivan Foeldvari, M.D.; Lisa Imundo, M.D.; Gabriele Simonini, M.D.; Joachim Oppermann, M.D.; Yaung-Kaung Shen, Ph.D.; Sudha Visvanathan, PhD, Adedigbo Fasanmade PhD, Alan Mendelsohn, M.D., FACC; Alberto Martini, M.D.; Prof., Edward H. Giannini, M.Sc., Dr.P.H., for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 718-22. Impact factor- 9,087
  47. Otylia Kowal-Bielecka1*, Jerome Avouac2*, David Pittrow3, Doerte Huscher4, Frank Behrens5, Christopher P Denton6, Ivan Foeldvari7, Marc Humbert8, Marco Matucci-Cerinic9 Peter Nash10, Christian F. Opitz11, Lewis J Rubin12, James R. Seibold13, Vibeke Strand14, Daniel E Furst15*, Oliver Distler16*, for the EPOSS group. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010, 37:105-15. Impact factor- 3,551
  48. Iris Vilca1*, Pablo Garcia Munitis1*, Angela Pistorio2, Angelo Ravelli3, Antonella Buoncompagni1, Blanca Bica4, Lucia Campos5, Renate Hafner6, Michael Hofer7, Seza Ozen8, Christian Huemer9, Sang Cheol Bae10, Flavio Sztajnbok11, Olga Arguedas1, Ivan Foeldvari12, Hans Iko Huppertz13, Mari Luz Gamir Gamir14, Bo Magnusson15, Frank Dressler16, Josef Uziel17, Renée van Soesberger18, Peter Hollingworth19, Gail Cawkwell20, Alberto Martini3, Nicolino Ruperto1 for the Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathich arthritis: analysis of the PRINTO methotrexate trial. Annals of Rheumatic Diseases. 2010;69:1479-1483. Impact factor- 9.087
  49. Dirk Foell, M.D., Nico Wulffraat, M.D., Lucy Wedderburn, M.D., Helmut Wittkowski, M.D., Michael Frosch, M.D., Joachim Gerß, Ph.D., Valda Stanevicha, M.D., Dimitrina Mihaylova, M.D., Virginia Ferriani, M.D., Florence Kanakoudi Tsakalidou, M.D., Ivan Foeldvari, M.D., Ruben Cuttica, M.D., Benito Gonzalez, M.D., Angelo Ravelli, M.D., Raju Khubchandani, M.D., Sheila Oliveira, M.D., Wineke Armbrust, M.D., Stella Garay, M.D., Jelena Vojinovic, M.D., Ximena Norambuena, M.D., María Luz Gamir, M.D., Julia Garcia Consuegra, M.D., Loredana Lepore, M.D., Gordana Susic, M.D., Fabrizia Corona, M.D., Pavla Dolezalova, M.D., Angela Pistorio, M.D., Ph.D.,Alberto Martini, M.D., Nicolino Ruperto, M.D., M.P.H., Johannes Roth, M.D., for the Paediatric Rheumatology INternational Trials Organization (PRINTO). Myeloid-Related Proteins 8 and 14 (MRP8/14) as biomarker for a risk-adapted treatment duration in juvenile idiopathic arthritis: Results of a randomized trial of 6 versus 12 months withdrawal of methotrexate. JAMA 2010, 303(13):1266-1273. Impact factor- 30,0
  50. Ivan Foeldvari and Angela Wierk. Effectiveness of Leflunomide in Patients with Juvenile Idiopathic Arthritis in Clinical Practice. J Rheumatol 2010, 37.1763-7. Impact factor- 3,551
  51. Nicolino Ruperto, Daniel J Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A Silva, Carlos Abud-Mendoza7, Ruben Burgos-Vargas,Valeria Gerloni, Jose A Melo-Gomes, Claudia Saad-Magalhães, J Chavez, Christian Huemer, Alan Kivitz, Francisco J Blanco, Ivan Foeldvari, Michael Hofer, Gerd Horneff, Hans-Iko Huppertz, Chantal Job Deslandre, Anna Loy, Kirsten Minden, Marilynn Punaro, Alejandro Flores Nunez, Leonard H Sigal, Alan J Block, Marleen Nys, Alberto Martini, Edward H Giannini, for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis Rheum 2010 Volume 62 Issue 6, Pages 1792 - 1802. Impact factor. 8,435
  52. Doerte Huscher1*, David Pittrow2*, Oliver Distler3, Christopher P Denton4, Ivan Foeldvari5, Marc Humbert6, Marco Matucci-Cerinic7, Otylia Kowal-Bielecka8, Jerome Avouac9, Frank Behrens10, Peter Nash11, Christian F. Opitz12, Lewis J Rubin13, James R. Seibold14 and Daniel E. Furst15 for the other coauthors of the EPOSS-OMERACT group† Interactions between rheumatologistst and cario-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology 2010, 28: 2 Suppl 58:S47-52. Impact factor- 2,4.
  53. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara LM, Morovic-Vergles J, Denton C, Hinrichs R, Van den Hoogen F, Damjanov N, Kötter I, Ortiz V, Heitmann S, Krasowska D, Seidel M, Hasler P, Van Laar JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wislowska M, Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A, Cossutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL, Steinbrink K, Herrick A, Müller-Ladner U, Dinc A, Scorza R, Sondergaard K, Indiveri F, Nielsen H, Szekanecz Z, Silver RM, Antivalle M, Espinosa IB, García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F, Tuvik P, Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M, Sunderkötter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J, Zeni S, Nash P, Mouthon L, De Keyser F, Duruöz MT, Cantatore FP, Strauss G, von Mülhen CA, Pozzi MR, Eyerich K, Szechinski J, Keiserman M, Houssiau FA, Román-Ivorra JA, Krummel-Lorenz B, Aringer M, Westhovens R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S, Granel B, Valderílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo Machado X, Pileckyte M, Stebbings S, Mathieu A, Tulli A, Tourinho T, Souza R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D, Francisco Marques Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed W, Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C, Vonk M, Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Hachulla E, Furst DE. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 ;37:148. Impact factor- 3,551.
  54. Ivan Foeldvari, Svetlana I. Nihtyanova2, Angela Wierk, Chris Denton. Characteristics of juvenile onset systemis sclerosis patients in an adult single centre cohort. Concise report. J Rheumatol 2010; 37:2422–6. Impact factor- 3,551
  55. G. Horneff, I. Foeldvari, K. Minden, , T. Hospach, Moebius Report on Malignancies in the German Juvenile Idiopathic Arthritis Registry.Rheumatology 2011;50:230-6. Impact factor- 4,171
  56. A.F. Jansson1, C. Sengler, J. Kuemmerle-Deschner, B. Gruhn4, B. Kranz, H. Lehmann6, B. Kleinert, L. Pape, D. Moebius, J. Peitz, D. Foell, H.J. Girschick, I. Foeldvari, J.P. Haas, D Haffner, V. Grote. B- cell depletion for autoiummune disease in pediatric patients. Clinical Rheumatology 2011, 30:87-97. Impact factor- 1,283
  57. Christopher P Denton, Jerome Avouac, Frank Behrens, Daniel E Furst, Ivan Foeldvari, Marc Humbert, Doerte Huscher, Otylia Kowal-Bielecka, Marco Matucci-Cerinic, Peter Nash, Christian F Opitz, David Pittrow, Lewis J Rubin, James R Seibold and Oliver Distler. Systemic sclerosis associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research & Therapy 2011,13: 114. Impact factor- 4,27
  58. Rudolf Mierau1, Pia Moinzadeh2, Gabriela Riemekasten3, Inga Melchers4, Michael Meurer5, Frank Reichenberger6, Michael Buslau7, Margitta Worm8, Norbert Blank9, Rüdiger Hein10, Ulf Müller-Ladner11, Annegret Kuhn12,13, Cord Sunderkoetter13, Aaron Juche14, Christiane Pfeiffer 15, Christoph Fiehn16, Michael Sticherling17, Percy Lehmann18, Rudolf Stadler19, Eckhard Schulze-Lohoff20, Cornelia Seitz21, Ivan Foeldvári22, Thomas Krieg2, Ekkehard Genth23, and Nicolas Hunzelmann2. Frequency of disease associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Research and Therapy. 2011 13: R 172. Impact factor- 4,27
  59. Dueckers Gregor*, Guellac Nihal*, Arbogast Martin, Dannecker Guenther, Foeldvari Ivan, Frosch Michael, Ganser Gerd, Heiligenhaus Arnd, Horneff Gerd, Illhardt Arnold, Kopp Ina, Krauspe Ruediger, Markus Barbara, Michels Hartmut, Schneider Matthias, Singendonk Wolfram, Sitter Helmut, Spamer Marianne, Wagner Norbert, Niehues, Tim. Evidence and consensus based GKJR guidelines 2010 for the treatment of juvenile idiopathic Arthritis (JIA) Klinische Pädiatrie 2011, 223: 386-94. Impact factor- NN
  60. Dueckers Gregor*, Guellac Nihal*, Arbogast Martin, Dannecker Guenther, Foeldvari Ivan, Frosch Michael, Ganser Gerd, Heiligenhaus Arnd, Horneff Gerd, Illhardt Arnold, Kopp Ina, Krauspe Ruediger, Markus Barbara, Michels Hartmut, Schneider Matthias, Singendonk Wolfram, Sitter Helmut, Spamer Marianne, Wagner Norbert, Niehues, Tim. Evidence and consensus based GKJR guidelines 2010 for the treatment of juvenile idiopathic Arthritis (JIA) Clinical Immunolog. 2012;142:176-193. Impact factor- 3,932
  61. Otylia Kowal-Bielecka1*, Jerome Avouac2*, David Pittrow3, Doerte Huscher4, Frank Behrens5, Christopher P Denton6, Ivan Foeldvari7, Marc Humbert8, Marco Matucci-Cerinic9 Peter Nash10, Christian F. Opitz11, Lewis J Rubin12, James R. Seibold13, Vibeke Strand14, Daniel E Furst15*, Oliver Distler16*, for the EPOSS group. Analysis of the validation status of the quality of life and functional disability measures in scleroderma-related pulmonary arterial hypertension. Results of a systematic literature analysis by the EPOSS (Expert Panel on Outcomes Measures in PAH related to Systemic Sclerosis) group. J Rheumatol 2011,38: 2419-27. Impact factor- 3,551
  62. Heiligenhaus, A, Michels, H.Schumacher, C.Kopp, I.Neudorf, U.Niehues, T.Baus, H.Becker, M.Bertram, B.Dannecker, G.Deuter, C.Foeldvari, I.Frosch, M.Ganser, G.Gaubitz, M.Gerdes, G.Horneff, G.Illhardt, A.Mackensen, F.Minden, K.Pleyer, U.Schneider, M.Wagner, N.Zierhut, M. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2011, 32:1121-33. Impact factor- 3,932
  63. I.Foeldvari , A.Tyndall A, F. Zulian , U. Muller-Lander, L. Czirjak, O. Kowal-Bielecka, D. Farge Bancel, M. Matucci-Cerinic on behalf of the members of EUSTAR. ( Co-Authors E.) Juvenile and young adult onset systemic sclerosis share the same organ involvement in adulthood: Data from the EUSTAR database.. Rheumatology 2012 2012,51:832-7. Impact factor- 4,171
  64. Minden K, Niewerth M, Zink A1, Seipelt E, Foeldvari I, Girschick H, Horneff G. Long-term outcome of patients with juvenile idiopathic arthritis (JIA) treated with Etanercept, results of the biologic register JuMBO. Rheumatology 2012, epub March 24.- Impact factor- 4,171
  65. Horneff G, Foeldvari I, Ganser G, Haas JP, Hospach A, Huppertz I. 10 Jahre Erfahrung im deutschen JIA Etanercept Register: Lehren aus wechselnden Patientenpopulationen. Arthritis +rheuma 2011;31:334-342- Impact factor- NN
  66. Heiligenhaus A*, Foeldvari I*, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Edelsten C, Graham E, Jordi A, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich CE, Ramanan AV, Strand V.* AH and IF contributed equally and share first authorship of this manuscript. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: recommendations from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) Arthritis Care and Research 2012, 64:1349-1356.- Impact factor- 4,749
  67. Klein, A, Kaul, I., Foeldvari, I., Ganser, G. Andreas, U.Horneff, G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis. An observational study with patients of the German Methotrexate Registry. Arthritis Care Res 2012; 64: 1349-1356 – Impact facto – 4,749
  68. Gerd Horneff1, Sigrid Fitter1, Ivan Foeldvari2, Kirsten Minden3, Jasmin Kuemmerle-Deschner4, Nicolay Tzaribacev5, Angelika Thon6, Michael Borte7, Gerd Ganser8, Rolf Trauzeddel9, Hans-Iko Huppertz10. Double blind, Placebo-controlled randomized trial with Adalimumab for Treatment of Juvenile Ankylosing Spondylitis (jAS): significant short term improvement. Arthritis Res Ther. 2012 Oct 24;14(5):R230. [Epub ahead of print] – Impact Factor 4,357
  69. NM Wulffraat and Bas Vastert for the SHARE consortium * :*The SHARE consortium consists of the following partners (alphabetical order): Jordi Anton (Spain), Tadej Avcin (Slovenia), Brigitte Bader-Meunier (France), Michael Beresford (UK), Paul Brogan (UK), Liza McCann (UK), Tamas Constantin (Hungary), Dennis Costello (Eurordis), Jasmin Kummerle Deschner(Germany), Pavla Dolezalova (Czech Republic), Gregor Dueckers (Germany), Ivan Foeldvari (Germany), Helen Foster (UK), Joost Frenkel (the Netherlands), Marco Gattorno (Italy), Marisa Giunta D’Albani (JIA Patient Organization, the Netherlands), Claudia Grave (JIA Patient Organization, Germany), Noortje Groot (the Netherlands), Veronique Hentgen (France), Gerd Horneff (Germany), Sylvia Kamphuis (the Netherlands), Isabelle Kone-Paut (France), Pekka Lahdenne (Finland), Bo Magnussen (Sweden), Alberto Martini (Italy), Kirsten Minden (Germany), JJ vd Net (the Netherlands), Seza Ozen (Turkey), Matthew Peak (UK), Clarissa Pilkington (UK), , Bas Vastert (the Netherlands), Carine Wouters (Belgium), Nico Wulffraat (the Netherlands), Pierre Quartier (France), Angelo Ravelli (Italy), Annet v Royen (the Netherlands), Ingrida Rumba (Latvia), Nicola Ruperto (Italy), Silvia Scala (Italy) and Francesco Zulian (Italy): Time to SHARE. Pediatric Rheumatology 2013 ; 11: 5. Impact Factor: 1,44
  70. Gerd Horneff, Ruben Burgos-Vargas, Tamas Costantin, Ivan Foeldvari, Jelena Vojinovic, Vyacheslav G. Chasnyk, Joke Dehoorne, Violeta Panaviene, Gordana Susic, Valda Stanevica, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Richard Mouy, Ingrida Rumba, Luciana Breda, Pavla Dolezalova, Chantal Job-deslandre, Nico Wulffraat, Daniel Alvarez, Chuanbo Zang, Joseph Wajdula, Deborah Woodworth, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto for the Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and Safety of Open-label Etanercept on Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, and Psoriatic Arthritis: Part 1 (Week 12) of the CLIPPER Study Annals Rheum Dis 2013, accepted . Impact factor- 9.087

nach oben

Übersichtsarbeiten:
  1. I. Foeldvari: Antikörper-Diagnostik bei rheumatologischen Erkrankungen im Kindesalter. Deutsches Ärzteblatt 1999,51/52:3288-3290. Impact factor- 2,1
  2. I. Foeldvari: Diffuse and limited cutaneous systemic sclerosis. Current Opinion In Rheumatology, 2000,12:.435-438. Impact factor- 4,497
  3. I. Foeldvari: Kinderrheumatologie. Eine junge Disziplin entwickelt sich. Hamburger Ärzteblatt 2000 , 6-7:258-60. Impact factor- NN
  4. I. Foeldvari, N. Wulffraat: Recognition and management of scleroderma in children. Pediatric Drugs 2001,3:575-583. Impact factor- 1,786
  5. I. Foeldvari: Selektive Cyclooxygenase 2 -Hemmer in der Kinderrheumatologie. Symposium Medical 2002,13:18-19. – Impact factor- NN
  6. I. Foeldvari: Diffuse and limited cutaneous systemic sclerosis. Current Opinion In Rheumatology, 2002,14:699-704. Impact factor- 4,497
  7. I. Foeldvari: Anwendung selektiver COX-2-Hemmer in der Kinderrheumatologie. Rheuma Aktuell, 2002/03:26-27. Impact factor- NN
  8. I Foeldvari: Welche Impfungen sind kontraindiziert? Pädiatrie Hautnah 2003, 15: 226-7. Impact factor Impact factor-NN
  9. I. Foeldvari. TNF- ? Antagonisten in der Kinderrheumatologie. Symposium medical 2004, 15: 32-33.
    Impact factor-NN
  10. I. Foeldvari : Systemic Sclerosis in Childhood. Rheumatology 2006, 45: iii28-iii29. Impact factor- 4,171
  11. Arnd Heiligenhaus1#, Gerd Horneff2, Kathrin Greiner3, Friederike Mackensen4, Manfred Zierhut5, Ivan Foeldvari6, Hartmut Michels7 TNF-Inhibitoren bei Arthritis und Uveitis im Kindesalter. Sonderheft der Klinischen Monatsblätter der Augenheilkunde 2007,.224: 526-31. Impact factor- 0,54
  12. I. Foeldvari. Update on juvenile systemic sclerosis. Current Opinion in Rheumatology, 2008, 20: 608-613. Impact factor- 4,497
  13. I. Foeldvari. Current Developments in Pediatric Systemic Sclerosis. Current Rheumatology Report 2009, 11:97 - 102. Impact factor- 0,9
  14. I Foeldvari – Koauthor an den nationalen Leitlinien des Kutanen Lupus Erythematodes. Entwicklungsstufe 1. – www.awmf.org/ www.derma.de - Annegret Kuhn1*, Merle Haust2, Elisabeth Aberer3, Caroline Barde4, Ivan Foeldvari5,Christof Iking-Konert6, Peter Kind7, Alexander Kreuter8, Percy Lehmann9, Thomas Luger1, Jann Lübbe4, Michael Meurer10, Ulf Müller-Ladner11, Falk Ochsendorf12, Vincent Ruland1, Thomas Ruzicka13, Matthias Schneider6, Michael Sticherling14, Beate Tebbe15, Jörg Wenzel16, Annette Wons1, Elke Weisshaar17, Gisela Bonsmann1Kutaner Lupus erythematodes: Teil 1. Diagnostik + Teil 2. Therapie. AWMF Leitlinien Stufe 1..
  15. I Foeldvari, J. Kuemmerle-Deschner. Klinik der autoinflammatorischen Erkrankungen im Kindesalter. Zeitschrift für Rheumatologie 2009,68: 726-732. ISSN 0340-1855. Impact factor- 0,447
  16. T. Constantin, I. Foeldvari . 18 éves életkor alatt alkalmazott anti-TNF támadáspontú biológiai terápiák alkalmazásának protokollja Juvenilis Idiopathias Arthritis indikációban- ( Ungarische Leitlinien zu anti TNF Therapie in Juvenile Idiopathische Arthritis). Immunology Quarterly 2011, 3: 19-22. Impact factor-NN
  17. Carsten Heinz, Arnd Heiligenhaus, Jasmin Kümmerle-Deschner, Ivan Földvari. Uveitis bei juveniler idiopathischer Arthritis (JIA). Zeitschrift für Rheumatologie 2010, 69:411–418 • DOI 10.1007/s00393-010-0656-7. Impact factor- 0,447
  18. I. Foeldvari. Editorial- Arthritis and Rheumatism- Methotrexat in juvenile localized scleroderma. Adding to the evidence. Arth Rheum 2011, 63: 1779-1781. Impact factor- 8,435
  19. Levy RA, de Andrade FA, Foeldvari I. Cutting-edge issues in autoimmune uveitis. Clin Rev Allergy Immunol. 2011 Oct;41(2):214-23. Impact factor- 3,435
  20. I. Foeldvar. H6c "Juvenile systemische Sklerodermie. Leitlinien im Kinder- und Jugendmedizin im Elsevier, Urban & Fischer Verlags Sektion H (Rheumatologie) für das Loseblattwerks. In print 2011- Impact factor- NN
  21. Dr. Constantin Tamás, Dr. Foeldvari Iván. 18 éves életkor alatt alkalmazott anti-TNF támadáspontú biológiai terápiák alkalmazásának protokollja Juvenilis Idiopathias Arthritis indikációban. Immunológiai Szemle. 2011; 1: 19-30. Impact factor- NN
  22. I. Foeldvari. New developments on the topics of Juvenile Systemic and Localized Scleroderma . Rheumatic Disease Clinics of North America. 2013 in print. Impact factor: 2.950
  23. I. Foeldvari. Update zur juvenilen systemischen Sklerodermie. Arthritis + Rheuma 2013, 33: 114-117
  24. A. Kienast. I Foeldvari. Hauterscheinungen bei rheumatischen Erkrankungen im Kindes und Jugendalter. Kinder- und Jugendarzt 2013, 44, 149-156.

nach oben

Beiträge zu Fachbüchern:

  1. C. Loeliger, I Foeldvari: Caucasian German juvenile rheumatoid arthritis. In P.I. Terasaki, D.W. Gjertson, Herausgeber. HLA 1997. Los Angeles: UCLA Tissue Typing Laboratory; 1997:407-8.
  2. M. Girschick, I. Foeldvari: Systemische Sklerose, progressive systemische Sklerodermie. In: Leitlinien der Kinderheilkunde und Jugendmedizin. München, Urban und Fischer; 1999:H7:36-39
  3. I. Foeldvari, E. Weissbarth-Riedel: Wegener Granulomatose und seltene Vaskulitiden. In: Leitlinien der Kinderheilkunde und Jugendmedizin. München, Urban und Fischer; 1999:H7:46-51
  4. Gromicka,-Ihle, I. Foeldvari. Phospholipidsyndrom. In: Rheumatische Erkrankungen im Kindes- und Jugendalter. München: Hans Marseille; 2001:274-286
  5. I. Foeldvari: Sklerodermie. In Rheumatische Erkrankungen des Kindes- und Jugendalter. München: Hans Marseille; 2001:296-303.
  6. I. Foeldvari, T. Niehues: Leitlinien zur Anwendung der Nicht Steroidalen Antirheumatika in der Kinder- und Jugendrheumatologie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004)
  7. G. Horneff, I. Foeldvari: Leitlinien zur Anwendung der Tumor Nekrosis- Alfa Blocker in der Kinder- und Jugendrheumatologie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004)
  8. I. Foeldvari, H. Girschick: Leitlinien zur Diagnose und Therapie der systemischen Sklerodermie. Für die Leitlinien der Kinderheilkunde und Jugendmedizin. (2004)
  9. I. Foeldvari. Sklerodermie und Sharp-Syndrom im “N. Wagner und G. Dannecker : Pädiatrische Rheumatologie- Buch, Springer 2007: 347-363.
  10. I. Foeldvari. Juvenile Systemic Sclerosis. Im Handbook of Systemic autoimmune diseases- Pediatrics. – First Edition - Elsevier 2008. 107-118. Herausgeber: T. Lehmann und R. Cimaz.
  11. Foeldvari. An 8-year-old girl with tight skin, digital ulcers, and dysphaiga. Case Studies in Systemic Sclerosis. Editors: Richard M. Silver and Christpher P. Denton. Springer 2011.
  12. I. Foeldvar. Juvenile systemic sclerosis. Page 93-103. Scleroderma – From Pathogenesis to comprehensive management. Editors J. Varga, C.P. Denton, F.M. Wigley. Springer 2012.
  13. I. Foeldvari. Sklerodermie und Sharp-Syndrom im “N. Wagner und G. Dannecker : Pädiatrische Rheumatologie- Buch, Springer 2013- in print
  14. Foeldvari, K. Reich Skin Manifestations of Neonatal Lupus Erythematosus. Rheumatic Diseases and the Skin, 1st Edition Elsevier 2013 – Herausgeber: Matucci-Cerinic in print
  15. I. Foeldvari. Up Date on Juvenile Systemic Sclerosis. Ebook chapter. Cutolo et al. 2013. Future in Medicine.

nach oben

Einladungen zu Vorträgen:
  1. Mai-Symposium der Rheumaklinik Wiesbaden II, Abklärung weichteilrheumatischer Symptome bei Kindern. (5/1995)
  2. Universitätskinderklinik Essen: „Rationelle diagnostische Nutzung von Autoantikörpern bei rheumatischen Erkrankungen im Kindesalter”. (6/1996)
  3. Universitätskinderklinik des Virchow-Klinikums, Berlin: „Rationelle diagnostische Nutzung von Autoantikörpern bei rheumatischen Erkrankungen im Kindesalter”.(7/1996)
  4. Fortbildungsabend der Vereinigung der Kinderärzte Hamburg e.V.: Untersuchung des rheumakranken Kindes in Praxis und Labor. (5/1997)
  5. Ärztlicher Verein, Fortbildungsakademie, Fortbildungsabend: Untersuchung von Kindern mit muskuloskeletalen Beschwerden in Praxis und Labor. (12/1997)
  6. Nycomed Pharma Rheumasymposium 1998, Oslo, Norwegen, Übersichtsvortrag: Sclerodermia, Prevalence, Diagnosis, Treatment. (4/1998)
  7. Fifth International Workshop on Scleroderma Research, July 19-21, 1998 Boston, Massachusetts, unterstützt vom National Institute of Health: „Survival in Pediatric Scleroderma“.
  8. Veranstaltung des Norddeutschen Zentrums zur Weiterentwicklung der Pflege: “Kinder-Welt”, workshop: „Diagnose: Lebenslänglich” (11/98).
  9. Interdisziplinäres Symposium, Universtitäts-Krankenhaus Eppendorf: „Nichtsteroidale Antirheumatika: Erkennung und Vermeidung unerwünschter Wirkungen.: Das Kind als Rheuma- Patient: Wo liegen die besonderen Probleme?“. (1999)
  10. Regionaltagung der Deutschen Gesellschaft für Rheumatologie, Warnemünde, 1999: Organisation und Vorsitz des Symposium der Arbeitsgemeinschaft Kinderrheumatologie, „Rationale Diagnostik der Gelenkbeschwerden im Kindes- und Jugendalter“ (Vortrag zusammen mit Dr. Dressler) (Zeitschrift für Rheumatologie, 1999, 58 (Suppl 1):I/19 S 44).
    „Transition Clinics für adoleszente Patienten“.
  11. Der besondere Fall. Aplastische Anämie und Thrombotische Thrombozytopenische Purpura bei einer Patientin mit systemischem Lupus erythematosus. Symposium der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie und der Niederländischen Arbeitsgemeinschaft Pädiatrische Rheumatologie. 21.01.2000, Sendenhorst.
  12. Scleroderma in Childhood. An Overview. National Paediatric Rheumatology Teaching Course at Great Ormond Street Hospital, in Cooperation with The Institute of Child Health, 02.24.2000, London, UK.
  13. Juvenile systemic sclerosis. An overview. Grand rounds. Children´s Hospital of Phialdelphia, University of Pennsylvania, Philadelphia, USA. 27. 03.2000.
  14. Results of the Phase I/II Study for Meloxciam, International Investigator Meeting Meloxicam, Boehringer Ingelheim, 02/02/2001, München, Germany.
  15. Juvenile systemic sclerosis and outcome. First International Workshop on Juvenile Scleroderma. 1-3 June 2001, Padua, Italy
  16. Juvenile Systemic sclerosis outcome and treatment. 01.08.2001, Rheumatology Rounds, Department of Immunology and Rheumatology, Childrens Memorial Hospital, Nortwestern University, Chicago, IL, USA
  17. Erste Ergebnisse der Anwendung von selektiven COX-2-Hemmern in der Kinderrheumatologie. 21.09.01, 30. Kongress der Deutschen Gesellschaft für Rheumatologie, Leipzig. Zeitschrift für Rheumatologie, 2001, 60, Suppl 1: I/16.
  18. Systemischer Lupus Erythematodes bei Neugeborenen und im Kindesalter. Veranstaltung zum 10-jährigen Jubiläum der Regionalgruppe Hamburg, LUPUS Erythematodes - Selbsthilfegemeinschaft. e.V. 24.08.02, Hamburg.
  19. COX-2 Hemmer bevorzugt? Eine kritische Bestandsaufnahme. Mittagssymposium, Deutscher Orthopädenkongress 2002 Berlin.
  20. Corticoidinduzierte Osteoporose bei juveniler rheumatoider Arthritis. Seminar des Regionalen Expertenkreises Osteoporose – Mitteldeutschland, 16.11.2002, Hannover.
  21. Juvenile Systemische Sklerodermie. 6. Kurs Pädiatrische Rheumatologie, 22.-23.11.2002, Bremen.
    Ambulante Versorgung rheumakranker Kinder. Symposium Rheuma bei Kindern – Neue Wege. Universitätskinderklinik Greifswald 08.02.2003.
  22. Immunsuppressive Therapie bei der kindlichen Uveitis. Fortbildung zum Thema Uveitis- aktuelle Aspekte. Universitäts-Augenklinik Hamburg-Eppendorf, 22.02.2003.
  23. Results of treatment with methotrexate for uveitis associated to juvenile idiopathic arthritis. Grand rounds. Rheumatology Department,MUSC, Charleston, South Carolina, 20.03.2003.
  24. Juvenile systemic sclerosis: clinical and laboratory features and outcome. Grand rounds, University Children´s Hospital, Padua, Italien, 30.05.2003.
  25. Klinische Präsentation, Therapie und Prognose der kindlichen systemischen Sklerodermie. 13. Jahrestagung der Arbeitsgemeinschaft für Kinder und Jugendrheumatologie. Aktuelle Rheumatologie, 2003, 28: 279, E.1.
  26. Pediatric skin scoring. OMERACT 7, 2004, Monterey , California, USA.
  27. Labordiagnostik von Autoimmunerkrankungen im Kindesalter. – Workshop - 12. Jahrestagung der Arbeitsgemeinschaft Pädiatrische Dermatologie, 09/2004.
  28. Sklerodermie im Kindesalter. Wörlitzer Gespräche, 02.10.2004.
  29. Update on uveitis treatment . National Brasilian Rheumatology Meeting, October 2004, Rio de Janeiro, Brasil.
  30. Scleroderma in children. Nationale Brasilian Rheumatology Meeting, October 2004, Rio de Janeiro, Brasil.
  31. Juvenile systemic sclerosis: Presentation of the planned inception cohort project. 1st Joint Cooperation Meeting of the German Network for Systemic Sclerosis (DNSS), Scientific Advisory Board, Köln, 17-18. December 2004.
    Das Hamburger Diagnostik- und Therapiekonzept für Kinder und Jugendliche mit juveniler idiopathischer Arthritis. 21.001.2005, Universitätsklinikum Hamburg-Eppendorf, Zentrum für Zahn-, Mund- und Kieferheilkunde.
  32. Scleroderma: how will we now learn more about this rare disease? – Old Challenges and New Directions in pediatric Rheumatology“ - Ross Petty Tribute Symposium 02.04.2005, Vancouver, Canada.
    Aktuelle Aspekte der Uveitisbehandlung bei Kindern - Immunomodulation. Am 22.06.2005- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Augenheilkunde.
  33. Formen der Sklerodermie im Kindesalter- Guide zum praktischen Vorgehen- Symposium Kinder- und Jugendrheumatologie- am 10.09.05 Klinik Sankt Augustin, Sankt Augustin.
  34. Sklerodermie im Kindesalter. 4. Erfurter Symposium – Autoimmunerkrankungen im Kindes und Jugendalter. 05.11.2005, Erfurt.
  35. Juvenile idiopathische Artritis – Therapie der Uveitis assoziiert zu JIA. Uveitis Seminar der Deutschen Arbeitsgemeinschaft für Uveitis und der Uveitis Selbsthilfegruppe in Zusammenarbeit mit der Universitäts Augenklinik Hamburg Eppendorf. 26.-27.11.2005 Hamburg.
  36. The eye in systemic disease – Is there an effective immunopsuppressive treatment for juvenile idiopathic arthritis associated uveitis? – II Congresso Latino-Americano De Autoimmunidade, Rio de Janiero, 28-30.04.2006, Brasilien.
  37. Sklerodermie – Seminar – im Rahmen der Netzwerk seltene Krankheiten: Beispel Bindegewebe. MEDICA 2006, 17.11.06 Düsseldorf
  38. Systemic Sclerosis in childhood – Professor E. Carwile LeRoy Memorial International workshop on Scleroderma. 17.-20.05.2007 , Tokyo, Japan.
  39. What makes children so spezial as patients? – Workshops on inflammatory disese in childhood: future challenges in paediatric uveitis. Annual Meeting of the European Society of Ophthalmology and the American Academy of Opthalmology. Wien 12.06.07.
  40. Juvenile Sklerodermie. 35. Kongress der Deutschen Gesellschaft für Rheumatologie, Hamburg, 19.-22.09.2007.
  41. Juvenile Skleroderma – DROP 2007 . Debrecen. Ungarn.. 16.11.2007.
  42. Therapie der juvenilen idiopathischen Arthritis. –Plenary Session- Jahresversammlung der ungarischen Kinderrheumatologen. Budapest. Ungarn. 01.12.,2007.
  43. Systemic Sclerosis World Symposium. Pediatric workshop- Clinical Presentation of juvenile systemic sclerosis . Organised by Actelion. Paris,France- 02.2008
  44. Diagnose und Behandlung der juvenilen idiopathischen Arthritis assoziierten Uveitis.
    25.04.2008, Barcleona. I. Reunion Nacional. Uveitis asociade a Arthritis Idiopatica Juvenil.
  45. Skin scores: what it tells us in adults in children. Invited speaker for the 15th Paediatric Rheumatology European Sociatey Congress. London 14.-17.09.2008.
  46. Systemic Sclerosis World Symposium. Pediatric workshop- Clinical Presentation of juvenile systemic sclerosis . Organised by Actelion. Basel,Switzerland. 27.02.-01.03.2009.
  47. Experts Meeting 2009- Evolving Concepts and treatment practices in systemisc IL-1ß-driven autoinflammatory disease. – Speaker- Ensuring more accurate diagnosis and better patient management through referrals. Organised by Novartis. Zürich, Switzerland. 08.-09.05.2009
  48. 2. Symposium – “Sport & Rheuma bei Kindern”- JIA: Wie sollen wir bei der Sport-Beratung vorgehen?- Garmisch-Partenkirchen, 09.05.09.
  49. Biologics in JIA. Kolloquium- The Impact if Biologics in the treatmet of arthritis. Technische Universität Zürich, Schweiz 01.10.09. I. Foeldvari. Bilogics in JIA.
  50. Sklerodermie und Kollagenosen –ZNS- Komplikation im Kindes- und Jugendalter.- Halle 26.02.10.- Symposium- Pädiatrische Neuromimmunologie“.
  51. Rheumatologische Diagnositik für benachbarte Fachdisziplinen. 2. Kieler CMD Konferenz – 19.-20.03.10.
  52. Diagnostik und Therapie aus rheumatologischer Sicht. XV. Kongress der German Board of Orthodontics and orofacial Orthopedics. Bonn. 17.-18.04.10
  53. Scleroderma – Diagnosis and Medical Managements and Uveitis Diagnosis and Managment at the Advaced Pediatric Rheumatology Course at Great Ormond Street Hospital, UK . 02.07.2010
  54. Faculty on the EUSTAR/EULAR course for the lecture: juvenile systemic scleoris, Belgrad, Serbia, 2011.
  55. Outcome Measures in Uveiits associated to juvenile idiopathic Arthritis. PRES Meeting Valencia 9.-12 09.2010.
  56. Besonderheiten und Languzeitprognose der juvenilen systemischen Sklerodermie. Übersichtsreferat. DGRH Kongress Hamburg 2010
  57. Enviromental influence on clinicla picture of FMF. 2 nd International Education meeting on Peridoidc Fever Syndromes and autoinfalmmatrory diseases. Budapest, Hungary. 22nd of October 2011.
  58. The TMJ survey results- how pediatric rheumatologists approach TMJ arthritis. 3rd Conference on TMJ Arthrritis in Children with Juveniler Idiopathischer Arthritis. 15-16.04.2011 Kiel, Germany
  59. Adaptation and Validation of Outcome Measures for Pediatric Uveitis. Pediatric Rheumatology study group at the American College of Rheumatology Meeting. 2011 Chicago, USA.
  60. Specific features of juvenile scleroderma. Annual meeting of the Groupe Francais de Recherche sur la Sclerodermie. 22nd of November 2011, Paris, France.
  61. Juvenile Scleroderma. Patient Programm. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain
  62. Faculty on the EUSTAR/EULAR course for the lecture: juvenile systemic scleoris, Cluj, Romanie, 2013.
  63. How to access systemic treatment efficacy in juvenile idiopathic arthritis associated arthritis. Plenary session talk. Second International congress on Controverises in Rheumatology & Autoimmunity (CORA) meeting, Budapest 2013.

nach oben

Vorträge auf Kongressen:

  1. J. Dippel, I. Foeldvari: Therapie der Juvenilen Polyartikulären Chronischen Arthritis. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde, Ulm 1989.
  2. I. Foeldvari, Y. Kimura, J.C. Jacobs: Macht Komplementdefizienz anfällig für SLE im Kindesalter? 1. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1991.
  3. I. Foeldvari: Häufigkeit von Antiphospholipid-Antikörpern bei kinderrheumatologischen Patienten. 2. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Göttingen, 1992.
  4. I. Foeldvari, C. Loeliger: Auffällige Häufung von Antiphospholipid-Antikörpern bei Eltern von Kindern mit juveniler oligoartikulärer Arthritis und SLE und deren Korrelation mit HLA-Loci. Vortrag zur 89. Jahrestagung der Kinderheilkunde Würzburg. Monatsschrift der Kinderheilkunde, 1993,141: (Supplement 1) 051 .
  5. I. Foeldvari, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Outcome of progressive systemic sclerosis (PSS) in childhood: Results of a multi-national questionnaire. (präsentiert zur “3. European Conference on Pediatric Diseases and Allied Disorders, 9/1995; Gent, Belgium. Clin Exp Rheumatol 1995;13: 554.
  6. I. Foeldvari, U. N. Birdi, P.B. Dent, R. Elborgh, F Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Progressive Systemische Sklerodermie (PSS) bei 94 Kindern: Ergebnis einer multinationalen Studie. Vortrag zur 5. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Freiburg i.Br., 1995, Monatsschrift Kinderheilkunde 1995; 143: 1052 V18.
  7. I .Foeldvari, C. Soost, R. Klein, C. Loeliger: Assoziation des Auftretens von Antiphospholipid-Antikörpern mit HLA-Merkmalen bei Kindern mit rheumatologischen Erkrankungen und ihren Eltern. Vortrag zur 6. Jahrestagung der Deutschen Gesellschaft für Kinderrheumatologie, Mühlheim an der Ruhr, 1996. Monatsschrift der Kinderheilkunde 1996; 144:1295.
  8. I. Foeldvari, M. Zhavania, N. Birdi, R.J. Cuttica, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, G. Ganser, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, R. Russo, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian: Günstigere Überlebenschance bei 135 Patienten mit juveniler systemischer Sklerodermie (jSSc): Ergebnisse einer multinationalen Studie. 8. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendmedizin, 10/98 Cottbus.
  9. I. Foeldvari., M. Redegeld, M. Mehrwald, D. Hülsebus, M. Bullinger. Gesundheitsbezogene Lebensqualität von Rheuma-betroffenen Kindern und Jugendlichen aus Elternsicht. Jahrestagung der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie und Pädiatrische Immunologie, Tübingen Mai 2000.
  10. B. Finckh, I. Foeldvari, D. Huelsebus, M. Mehrwald, A. Kohlschütter: Changes of antioxidative status and lipid peroxidation in juvenile idiopathic arthritis over a period of three months. 10th Biennial Meeting of the International Society for Free Radical Research. Abstract No. 002-5 (Reference No.: 100) Kyoto, Japan, 10/2000.
  11. G. Horneff, I. Foeldvari, R.M. Küster, H. Michles, D. Moebius, H. Schmeling, A. Thon: Etanercept for the treatment of juvenile idiopathic arthritis: results of the German registry. Ann Rheum Disease 2002, 61,Suppl 1: 52 – OP 0062.
  12. I. Foeldvari: Steroid induzierte Osteoporose bei Kindern mit kinderheumatologischen Erkrankungen? Ergebnisse einer Pilotstudie. Zeitschrift für Rheumatologie, 2002, 61 (Suppl. 1.): I/64 (PDG 11)
  13. I. Foeldvari: Es zeigt sich eine sehr gute Verträglichkeit von Vioxx? in der Anwendungsbeobachtung. 12. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendrheumatologie. Aktuelle Rheumatologie 2002, 27 :276 (36).
  14. G. Horneff , T. Biedermann, I. Foeldvari, et al. Combination therapy with methotrexat and etanercept compared to etanercept monotherapy. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 540
  15. G. Martini, I. Foeldvari, R.Russo, et al. Juvenile systemic sclerosisand related disorders: an international multicentre data collection of 181 patients. Xth European Pediatric Rheumatology Congress. Clinical Experimental Rheumatology 2003, 21: 551
  16. K. Minden, M. Niewerth, G. Ganser, RM Küster, D. Möbius, I. Foeldvari, A. Zink: Therapiekontinuität bei der juvenilen idiopathischen Arthritis. 13. Jahrestagung der Arbeitsgemeinschaft für Kinder und Jugendrheumatologie. Aktuelle Rheumatologie, 2003, 28: 282, F.6.
  17. I. Foeldvari, A. Wierk. Results of leflunomide (LEF) therapy in patients with juvenile idiopathic arthritis (JIA): A pilot noncontrolled therapeutic intervention. EULAR 2004 , Berlin, Ann Rheum Dis 2004, 61 (Supll 1.): 80 – OP 0076.
  18. I. Foeldvari, A. Wierk. Kann man in der pädiatrischen Population den modifizierten Rodnan Skin Score ohne Adaptation anwenden? Zeitschrift für Rheumatologie 2004, 63: 274- F.3.
  19. N.Ruperto, DJ. Lovell, S. Goodmann, A. Reiff, L. Jung, D.Nmecova, K. Jarosova, AM: Prieur, C. Sandborg, R. Joos, I. Foeldvari, et,al. Preliminary data from the open label phase of he randomized trial of adalimumab in children with juvenile idiopathic arthritis. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:522.
  20. I. Foeldvari, A. Wierk: Helathy children have a significantly increased skin score assessed with the modified Rodnan skin score. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:527.
  21. N. Ruperto, A. Ravelli, S.Olivieri, E. Silverman, G. espada, D. Mihaylova, S. Pasic, S. Ozen, M. Apaz, B. Bica, D. nemcova, R. Burgos-Varagas, F. Corona, AM. Romicka, J. Consuegra, S. Hagleberg, C Da Silva, C. Coto, Y. Uziel, J. Ros, MI. Gamir, I. Foeldvari, et, al. The validated PRINTO core set and definition of improvement for juvenile systemic lupus erythematosus. PRES 2004, Kosice, Slovakia. Clin exp Rheum 2004, 22:510.
  22. G. Horneff, R. Küster, H. Girschick, I. Foeldvari, D. Moebius. Safety of etanercept for treatment of juvenile idiopathic arthritis (JIA) – data of the German etanercept JIA registry. EULAR 2005, Wien , Österreich. Ann Rheum Dis 2005, 64 , Supplement III: 72 – OP 0048.
  23. C. Boschau, O. Witt, L. Schweigerer, P. Lohse, I. Foeldvari, H. Zappel. Neonatal-onset multisystem inflammatory disease (NOMID): new mutation of the CIAS1 gene and response to interleukin-1 recptor antagonist treatment. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-3, I/29.
  24. I. Foeldvari, S. Nielson, J. Kümmerle-Deschner, T. Sauerenman. Ergebnisse der multinationalen Befragung über die Anwendung der Tumor Nekrosis Faktor alpha Blocker in der Behandlung der JIA assoziierten Uveitis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ3-7, I/30.
  25. M. Niewerth, K. Minden, I. Foeldvari, G. Ganser, A. Zink. Übergewicht – ein Thema bei rheumakranken Kindern und Jugendlichen? Gewichtsstatus bei Patienten mit juveniler idiopathischer Arthritis. 15. Tagung der Arbeitsgemeinschaft für Kinder- nd Jugendrheumatologie, 2005 Dresden. Zeitschrift für Rheumatologie 2005, 64 (Suppl 1): FKJ2-5, I/28.
  26. F. Zulian, P. Woo, B.H. Athreya, R. laxer, T.A. Medsger, T.A. Lehman, M. Matucci-Cerinic, G. Martini, A. Ravelli, R. Russo, R. Cuttica, S.F.K. De Oliveira, C. Denton, I. Foeldvari, N. Ruperto. Preliminary classification criteria for systemic sclerosis in children. XII. European Pediatric Rheumatology Congress, Versaille, Frankreich 2005. Clinical Exp Rheumatol 2005; 23 (Suppl 37): S-47.
  27. G. Horneff, H. Girschick, I. Foeldvari, H. Michels, B. Rogalski, H. Schmeling: Combination therapy with etanercept and methotrexate compared to etanercept monotherapy in patients with juvenile idiopathic arthritis. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1955.
  28. N. Ruperto, D.J. Lovell, S. Goodman, A. Reiff, L.Jung, D: Nemcova, K. Jarosova, A. Prieur,C. Sanborg, R. Joos, I. Foeldvari, V. Gerloni, J. Rovensky, J. Bohnsack, K.Minden, L. Wagner-Weiner, R. Vehe, H. Huppertz, G. Horneff,N. Olson, J. Medich, E.H. Giannini, A. Martini: 48 week data from the study of adalimumab in children with juvenile rheumatoid arthritis. Annual European Congress of Rheumatology, 2006, Amsterdam, Holland. Ann Rheum Dis 2006, 65 Suppl II: 56.
  29. I.Foeldvari, A. Heiligenhaus, C.Tappeiner,S. Nielson, N. Tzaribachev, J. Quitsch, F. Dressler, M.O. Hilario, R.M. Küster, M. Borte, H. Mazu, E. Jäger-Roman, A. Wierk: Ergebnisse einer mulitnationalen Befragung zur Anwendung von Cyclopsporinb-A (CSA) in der Behandlung von Uveitis assoziiert mit juvenilen idiopathischen Arthritis (JIA). 16. Jahrestagung der Gessellschaft für Kinder- und Jugendrheumatologie , Leipzig 2006. Kinder- und Jugendmedizin 2006; 6: A 50, Abstact 39.
  30. G. Horneff, I. Foeldvari, J. Roth, H. Michels, M. Borte, H. Schmeling. Efficacy and tolerability of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. 2006 Annual Scientific Meeting of the American College of Rheumatology, Washington. Arth Rheumatism 2006, 54 (Suppl):S327 A 722.
  31. O. Kowal-Bielecka, R. Landews, J. Avouac, S. Chwiesko, L. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Foeldvari,... et al. EULA/EUSTAR recommendation for the management of systemic sclerosis. THU0281, EULAR 2007 Barcelona.
  32. I. Foeldvari, C. Wotuers, T. Avcin, F. Zulian. Results of a multinationla survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OPO185, EULAR 2007, Barcelona.
  33. F.Zulian, O.Kowal-Bielecka, I. Miniati, J. Avouac,SChwiesko, A. Aggarwal, BH Atreya, T. Avcin, R. Cuttica, SDKF de Oliveira, G. Higgins, RM Laxer, C. Lindsley, TH Lehman, G Martini, A Ravelli, R Russ, Y Uziel, C Wouters, I Foeldvari, EUSTR/Eular commitess on SSc management recommendations. Preliminary agreement of the Pediatric Rheumatology European Society(PRES) in the EUSTAR/EULAR redommendations for the management of systemic sclerosis in children. OP-17 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  34. I Foeldvari, C Wouters, T Avcin, F Zulian. Results of a multinational survey regarding preferences of paediatric rheumatologists in the treatment of juvenile systemic sclerosis. OP-19 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  35. I Foeldvari, A Wierk. Leflunomide is an effective alternative in the treatment for patients with juvenile idiopathic arthritis. OP-30 on the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  36. O Distler, D Pittrow, F Behrens, D Huescher, C Denton, I Foeldvari, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphie consensus study with cluster analysis. ACR 2007, Boston. Arthritis Rheumatism 2007, 56 (Suppl): A 2164, S 824
  37. I. Foeldvari. The prospective juvenile systemic sclerosis inceptions cohort. 1st Conference on Translational Research I Pediatric Rheumatology. Genoa , Italy.2008.
  38. D Lovell, R Cuttica, P Woo, G Espada, C Wouters, ED Silverman, Z Balogh, M Henricksen, J Davidson, I Foeldvari, L Imundo, G Simonini, J Oppermann, YK Shen, S Visvanathan, A Fasanmade et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course JRA: findings from the open label treatment extension. Annual PRES meeting London, UK 2008.
  39. A randomised trial of 6 months versus 12 months withdrawal of methotrexate in children with juvenile idiopathic arthritis in clinical remission.. D. Foell, N. Wulffraat, L.R. Wedderburn, A. Pistorio, A. Ravelli, V. Stanevicha, D. Mihaylova, V.P.L. Ferriani, F. Kanakoudi Tsakalidou, I. Foeldvari, R. Cuttica, B. Gonzalez4, R. Khubchandani, S.K.F. Oliveira, W. Armbrust, S.M. Garay, J. Vojinovic, X. Norambuena, M. Gamir, J. Garcia Consuegra, L. Lepore, G. Susic, F. Corona4, P. Dolezalova, T. Saurenmann, Y. Uziel, A. Martini, N. Ruperto, for PRINTO
    EULAR 2009 [THU0413], Copenhagen, Denmark.
  40. N. Ruperto, D.J. Lovell, R. Mouy, E. Paz, N. Rubio-Perez, C.A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J.A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez1, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, M. Hofer, G. Horneff1, H. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. Flores Nunez, L.H. Sigal, A.J. Block, A. Covucci, A. Martini, E.H. Giannini. Long-term safety and efficacy of abatacept in subjects with polyarticular juvenile idiopathich arthritis. OP- 0268 EULAR 2009 [THU0413], Copenhagen. Denmark.
  41. J.B. Kuemmerle Deschner, R. Cartwright, M. Gattorno, F. Zulian, P. Quartier, J. Hoyer, I. Foeldvari, E. Ramos, P.N. Hawkins, K. Leslie, G. Krammer, S. Malfait, R. Preiss, A. Widmer and E. Hachulla. Safety and effecacy of canakinumab in children accross different disease severity and phenotypes of cryopyrin associated periodic syndrome (CAPS): intermin results of an ongoing study. ACR 2009 Philadelphia, USA, Arthritis Rheum 2009, 60: #2056.
  42. P Quartier, E Hachulla, M Gattorno, R Cartwright, I Kone-Paut, F Zulian, E Weisbarth-Riedel, L Lepore, J Hoyer, I Foeldvari, E Ramos, P N Hawkins, K Leslie, G Krammer, R Preiss, A Widmer, J B Kuemmerle-Deschner. Canakinumab (ILARIS®) Provides Rapid Response and Sustained Remission in Children across Different Disease Severity Phenotypes of Cryopyrin Associated Periodic Syndrome (CAPS). ACR 2010. Arth Rheum 2010, 62.
  43. I. Foeldvari, A. Wierk, D. Farge. When is autologous bone marrow transplantation indicated in juvenile systemic sclerosis. Results of a multinational survey of pediatric rheumatologist. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain. Rheumatology 2012, Volume 51, Supplement 2; S1.4. ii2.
  44. I Foeldvari . Looking for minimal standards in care of children with localised scleroderma. Resutls of the consensus meeting in Hambug Germany on the 11th of December 2011. DGRH 2012 Bochum
  45. D. J. Lovell1, N. Ruperto2, R. Mouy2, E. Paz2, N. Rubio-Perez2, C. A. Silva2,C. Abud-Mendoza2, R. Burgos-Vargas2, V. Gerloni2, J. A. Melo-Gomes2, C ,Saad-Magalhaes2, J. Chavez2, C. Huemer2, A. Kivitz2, F. Blanco2, I. Foeldvari2, Michael Hofer3, H. Huppertz2, C. Job Deslandre2, K. Minden2, A. Flores Nunez4, A. J. Block5 and A. Martini2. 1Cincinnati Children’s Hospital, Cincinnati, OH, 2PRINTO, IRCCS G. Gaslini, Genoa, Italy, 3Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 4PRINTO, IRCCS Hospital para el Nin˜o Poblano, Puebla, Mexico, 5Bristol-Myers Squibb, Princeton, NJ. Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up. Arth Rheum 2012, 64:S 717 A 1679

nach oben

Letters:

  1. I. Foeldvari : Regarding the possible association of juvenile rheumatoid arthritis, Crohn’s disease and Turner’s syndrome. Letter to the editor. Clin Exp Rheumatol 1997; 15: 120.
  2. I. Foeldvari: Progressive linear scleroderma and morphea in a child. Insights in Pediatrics. J Pediatrics 1988;133:308.
  3. I. Foeldvari: Results of the multinational survey regarding feasibility-study for a therapeutic trial in juvenile systemic sclerosis. Letter. Clinical and Experimental Rheumatology 2000,18: 424.
  4. I. Foeldvari : Do we need a pediatric rheumatologist? - The Hamburg Experience. Letter to the editor. Arth Rheumatism 1999,42:396.
  5. I. Foeldvari: Anti-keratin antibodies in patients with JIA. Letter. Clin Exp Rheumatol 2001;19:762.
  6. I. Foeldvari: A selective COX-2 inhibitor, meloxicam, as treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen. Letter. Clinical Exp Rheumatol 2002,20:874.
  7. I. Foeldvari, T. Schneider: Acute, non-obstructive, sterile cholecystitis associated with Etanercept and Remicade for the treatmetn of juvenile polyarticular rheumatoid arthritis. Annals of Rheum Dis 2003, 62: 908-909.
  8. I. Foelevari, A. Wierk. Methotrexate and chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2006, 33: 198 – Impact factor – 3,551

nach oben

Eingereicht:

  1. Martina Niewerth, Kirsten Minden, Ivan Foeldvari, Gerd Ganser, Angela Zink. Prevalence of overweight among children and adolescents with juvenile idiopathic arthritis. ( Annals of Rheumatic Diseases )
  2. SC Li, MS Liebling, TArkachaisri, A Doria, F Ramji, A Mohanta
    E Pope, K Haines, M Punaro, G Higgins, CE Rabinovich, I Foeldvari, S ZhangKM ONeil. Formation of an international pediatric localized scleroderma outcome measures group: report of preliminary ultrasound disease activity and damage measures. (Clinical Experimental Rheumatology- submitted)
  3. Thome N1, Foeldvari I2, Huppertz HI3, Urban A4, Horneff G1. Etanercept and Leflunomid Combination Therapy in Juvenile Idiopathic Arthritis ( J Rheumatol submitted)
  4. I.Foeldvari 1 , S. Nielsen2, J. Anton Lopez3 , G. Reuter4, E. Hoppenrijs5, S. K. Feitosa de Oliveira, B.Fiebig7,N. Tzaribachev8,W. Mannhardt-Laakmann9, H. Mazur10, J. Walsh11, R. Joost12, A. Wierk1 . Results of a multinational survey regarding the efficacy of methotrexate in the treatment of juvenile idiopathic arthritis associated uveitis. ( submitted )
  5. Jerome Avouec, Frank Behrens , Daniel E Furst , Ivan Foeldvari , Marc Humbert , Dörte Huscher , Otylia Kowal-Bielecka , Marco Matucci-Cerinic , Peter Thomas Nash, Christian F Opitz , David Pittrow , Lewis Rubin , James R Seibold, Oliver Distler. Systemic sclerosis associated pulmonary hypertension: disease specific composite endpoints are needed. Submitted
  6. A. Kienast und I. Foeldvari. Hauterscheinungen bei Rheumatische Erkrankungen im Kindesalter. Schwerpunktheft "Kinderdermatologie"- Zetischrift Kinder und Jugendarzt (2013)
  7. Marek Bohm1,2, Maria Isabel Gonzalez Fernandez1, Seza Ozen3, Angela Pistorio4, Pavla Dolezalova2, Paul Brogan5, Giancarlo Barbano6, Claudia Sangler7, Marisa Klein-Gitelman8, Pierre Quartier9, Anders Fasth10, Troels Herlin11, Claudio Len12, Susan Nielsen13, Marion A.J. van Rossum14, Tadej Avcin15, Esteban Rodolfo Castell16, Ivan Foeldvari17, Dirk Foell18, Anuela Kondi19, Isabelle Koné-Paut20, Rolf-Michael Kuester21, Hartmut Michels22, Nico Wulffraat23, Halima Ben Amer24, Clara Malattia,25 Alberto Martini1,25, Nicolino Ruperto1, for the Paediatric Rheumatology International Trials Organisation (PRINTO). CLINICAL FEATURES OF CHILDHOOD GRANULOMATOSIS WITH POLYANGIITIS (WEGENER`S GRANULOMATOSIS). Rheumatology
  8. Ivan Foeldvari1*, Nikolay Tzaribachev2, Angela Wierk1, Randy Cron3. Update of the results of a multinational survey regarding diagnosis and treatment of the temporomandibulare joint involvement in juvenile idiopathic arthritis- reflection of the day to day practice. Pediatric Rheumatology

nach oben

Poster-Präsentationen mit veröffentlichten Abstracts:

  1. I.Foeldvari, Y.Kimura, J.C.Jacobs: Congenital complement deficiency in childhood lupus: 17% require little or no treatment. Arthritis Rheum 1990; 33:S144, D63.
  2. S. Lederman, M.J.Yellin, J.A.DeMartino, B.L. Daugherty, I. Foeldvari, A.M.C. Cleary, G.E. Mark and L. Chess: Regulation of T-cell functions by the CD4 molecule: Analysis of CD4- leukemic mutant before and after stable expression of CD4 cDNA. FASEB (AAI).61551:1991.
  3. S. Lederman, J.A. DeMartino, B.L. Daugherty, M.J. Yellin, I. Foeldvari, A.M. Cleary, G.E. Mark and L. Chess. Molecular functional characterisation of a common African allele of the CD4 molecule. Clin Research. Seattle 1991. N37-0007.
  4. S. Lederman, M.J. Yellin, J.A. DeMartino, B.L. Daughery, I. Foeldvari, A.M. Cleary, G. Mark and L. Chess: Mechanism of inducing B cell differentiation by a CD4-Jurkat clone: Surface features other than the lack of CD4 account for its constitutive ability to induce B cell activation. Clin Research. Seattle 1991. A36-0013.
  5. Y.Kimura, I. Foeldvari, J.C. Jacobs: Azathioprine is a valuable agent in the treatment of pediatric lupus nephritis. Pediatric Research 1991; 29 (#4, Pt.2): 345A.
  6. Y. Kimura, I. Foeldvari, J.C. Jacobs: Azathioprine is a valuable agent in the treatment of pediatric lupus nephritis. Lupus 1992; 1: S167.
  7. I. Foeldvari: Prevalence of antiphospholipid antibodies in pediatric rheumatologic patients. Arthritis Rheum 1992; 35:S95, A162.
  8. I. Foeldvari: The whole spectrum of expression of antiphospholipid antibodies in a family of 5. Arthritis Rheum 1992; 35: S356.
  9. I. Foeldvari, C. Loeliger: Is there a HLA linkage with antiphospholipid antibodies in juvenile rheumatoid oligoarthritis? 1st European Conference on Pediatric Autoimmune and Rheumatic diseases (1993). Abstract book, GN4.
  10. I. Foeldvari, T. Lehman: Is Methotrexate a new perspective in the treatment of Juvenile Progressive Systemic Scleroderma? 57th Annual Scientific Meeting of the American College of Rheumatology. Arthritis Rheum 1993; 36: (Suppl.) S218.
  11. I. Foeldvari, C. Loeliger: Are Antiphospholipid Antibodies in JRA inherited? 57th Annual Scientific Meeting of the American College of Rheumatology. Arthritis Rheum 1993; 36: (Suppl.) S173.
  12. I. Foeldvari, T. Lehman: Ist Methotrexat eine neue Perspektive in der Behandlung Juveniler Systemischer Progressiver Sklerodermie? Zeitschrift für Rheumatologie, 1993; 52:58K.
  13. I. Foeldvari, R. Klein: Increased frequency of antikeratin antibodies in subset of children with oligoarticulare onset JRA who are positive for antiphospholipid antibodies. 2nd European Conference on Pediatric Autoimmmune and Rheumatic Diseases, Pavia, Italy, Clinical and Experimental Rheumatology 1994;12/S-10:121.
  14. I. Foeldvari, R.E. Petty: Antibodies to human endothelial cells and cardiolipin in children with juvenile rheumatoid arthritis. 23rd Western Regional ACR Meeting (3/1995). Arthritis Rheum 1995; 38, No. 6 (Suppl) R9: Abstract 14.
  15. I. Foeldvari, M. Zhavania, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, R. Häfner, R. Joos, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Outcome of progressive systemic sclerosis (PSS) in 94 children: Results of a multi-national questionnaire. 59th National Meeting of the American College of Rheumatology; Art. Rheum 1995; 38 (Suppl): 1105.
  16. I Foeldvari, M. Zhavania, N. Birdi, P.B. Dent, R. Elborgh, F. Falcini, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Progressive systemic sclerosis (PSS) in 105 children showed a favourable outcome: Results of a multi-national questionnaire. 4th European Conference on Pediatric Rheumatology; Clinical Experimental Rheumatology 1996; 14: 465, A-74.
  17. I. Foeldvari, R.E. Petty: Antibodies to human endothelial cells (aECA) and cardiolipin (aCL) in children with juvenile rheumatoid arthritis. 4th European Congress on Pediatric Rheumatology, Clin Exp Rheum 1996; 14: 459, A-42.
  18. I. Foeldvari, M. Zhavania, N. Birdi, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, J.P. Garrahan, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty. Progressive systemic sclerosis (PSS) in 119 children showed a favourable outcome: Results of a multi-national questionnaire. 5th European Conference on Pediatric Rheumatology, Garmisch-Partenkirchen. Rev.Rheum. (Engl.Ed.) 1997; 64: 228: F 10.
  19. I. Foeldvari, M. Zhavania, N. Birdi, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, J.P. Garrahan, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, A. Savolainen, A. Siamopoulou-Mayridou, F. Zulian, R.E. Petty. Progressive systemic sclerosis (PSS) in 120 children showed a favourable outcome: Results of a multi-national questionnaire. 61st National Meeting of the American College of Rheumatology, Washington, USA 11/97. Arthritis Rheumatism 1997, 40 (Suppl) Abstract 426.
  20. I. Foeldvari, M. Zhavania, N. Birdi, R.J. Cuttica, S.H.F. de Oliveira, P.B. Dent, R. Elborgh, F. Falcini, G. Ganser, J.P. Garrahan, H. Girschick, R. Häfner, R. Joos, W. Kuis, P. Pelkonen, A.M. Prieur, K. Rostropowicz-Denisiewicz, R. Russo, A. Savolainen, A Siamopoulou-Mayridou, F. Zulian, R.E. Petty: Results of the multinational survey regarding outcome and clinical practice in juvenile systemic sclerosis: Summary of the data of 135 patients. 62nd Annual Congress of the American College of Rheumatology, 11/98 San Diego,USA. Arthritis Rheumatism 1998, 41 (Suppl) Abstract 1403.
  21. I. Foeldvari, M. Birdi: Validation of the proposed Durban classification criteria for juvenile idiopathic arthritis in the patient population of the pediatric rheumatology Clinic in Hamburg, Germany. VI. European Paediatric Rheumatology Congress, 1999 Glasgow, UK. Annals of the Rheumatic Diseases 1999; Supplement XIV EULAR Congress: 322 (A 1344).
  22. I Foeldvari, R. Burgos-Vargas; R. Linke: Preliminary results of a phase I/II study of meloxicam oral suspension in juvenile rheumatoid arthritis indicate high clinical response. 6th European Paediatric Rheumatology Congress, 1999 Glasgow, UK. Annals of the Rheumatic Diseases 1999; Supplement XIV EULAR Congress: 342 (A 1386).
  23. B. Finckh, I. Foeldvari, D. Hülsebus, M. Meerwald, A. Kohlschütter. Changes of the pro/antioxidant balance in different subsets of juvenile idiopathic arthritis. 63rd Annual Congress of the American College of Rheumatology, Boston, USA, 1999. Arthritis Rheumatism 1999, 42 (Suppl) Abstract 665.
  24. B. Finckh, I. Foeldvari, D. Huelsebus, M. Mehrwald, A. Kohlschütter: Differences in antioxidative status and free radical damage in juvenile idiopathic arthritis (JIA). 6th Annual Meeting of the Oxygen Society, New Orleans, USA, 1999. Free Radical Biol Med 1999, 27: S 121.
  25. I. Foeldvari, R. Burgos-Vargas, A. Thon: 70% of the patients are responders after 12 weeks in the phase I/II study of meloxicam suspension in juvenile rheumatoid arthritis. Annual European Congress on Rheumatology- EULAR 2000, Nice, France. Annals of the Rheumatic Diseases 2000, 59 (Supppl 1): 252, POS-824.
  26. I Foeldvari, C. Grave: Do we need a pediatric rheumatologist? - The Hamburg experience. Park City IV. Pediatric Rheumatology into the next century. Organised by the American Academy of Pediatrics. J Rheumatol 2000, 27 (Suppl 58): 102.
  27. I. Foeldvari, A. Thon, R. Burgos-Vargas: 70% der Patienten mit juveniler rheumatoider Arthritis sprachen nach 12 Wochen auf eine Therapie mit Meloxicam-Suspension im Rahmen einer Phase I/II Studie an. Zeitschrift für Rheumatologie 2000, 59 (Suppl 3): 49 , P 60.
  28. B. Finckh, I. Foeldvari, M. Mehrwald, D. Huelsebus, A. Kohlschütter: Changes of antioxidative status and free radical damage in subsets of juvenile idiopathic arthritis (JIA) over a period of three months. Ann Rheum Dis 2000; 59: 729 (A 7.1.)
  29. I. Foeldvari, M. Redegeld, M. Mehrwald, D. Hülsebus, M. Bullinger: Health related quality of life ( HRQoL) of children with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2000; 59: 734: (7..27)
  30. Ruperto, Murray, Bae, Prieur, Balogh, De Innocencia, Duarte, Foeldvari et. al. Part II. A generic instrument: the Child Health Questionnaire (CHQ). Ann Rheum Dis 2000; 59: 726 (A 4.20).
  31. I. Foeldvari, R. Burgos-Vargas, A. Thon, D. Tuerck: Pharmacokinetics and clinical outcome of Meloxicam in juvenile rheumatoid arthritis. Ann Rheum Dis 2000; 59: 745 (A 11.26).
  32. B. Finckh, I. Foeldvari, M. Mehrwald, D. Huelsebus, A. Koehlschuetter: Decrease of inflammatory disease activity parallels decrease of oxidative stress in juvenile idiopathic arthritis. Arth Rheum 2000,43 Suppl: S 357, A 1743.
  33. I. Foeldvari, R. Burgos-Vargas, A. Thon: Long-term efficiacy and safety of meloxicam in juvenile rheumatoid arthritis. Arth Rheum 2000,43 Suppl: S 121 A 326.
  34. K. Meyer, I. Foeldvari, L. Huck, S. Haubrich, B. Kahl-Nieke: Dentofacial morphology and temporomandibulare (TMJ) aspects in children with juvenile idiopathic arthritis. Arth Rheum 2000,43 Suppl: S 120, A: 321.
  35. Machado, Ruperto, Murray, Bae, Prieur, Balogh, de Inocencia, Duarte, Foeldvari et al.: Inquerito internacional em 29 paises sobre qualidade de vida relacionada a saude em artrites idiopathicas juvenis: Parte II por meio de um instrumento generico – CHQ. Revista Brasileira de Rheumatologia 2000, 40 Suppl 1: S27, A TL-020.
  36. I. Foeldvari: A selective COX-2 inhibitor, meloxicam (MX), as an effective alternative for treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2001, 60 Suppl 11: ii44 P 153.
  37. I. Foeldvari: Results of leflunomide therapy in patients with juvenile idiopathic arthritis (JIA): a pilot noncontrolled therapeutic intervention. Ann Rheum Dis 2002, 61 Suppl 1: 235 – FRI 0273.
  38. T. Schneider, E. Krüger, I. Foeldvari: Akute nicht obstruktive Cholecystitis – eine bisher bei Kindern nicht beschriebene Nebenwirkung von Enbrel (Etanercept) ?! Monatsschrift der Kinderheilkunde 2002, 150; 389.
  39. G. Horneff, T. Biedermann, I. Foeldvari et al: The German etanercept registry for treatment of juvenile idiopathic arthritis. Arth Rheumatism 2002, 46 (Suppl) S482 , A 1279.
  40. I. Foeldvari, A. Wierk.: Ergebnisse der Leflunomide (LEF) – Therapie bei Patienten mit juveniler idiopathischer Arthritis (JIA). 12. Jahrestagung der Arbeitsgemeinschaft für Kinder- und Jugendrheumatologie. Aktuelle Rheumatologie 2002, 27 : 277 (39).
  41. N. Ruperto, N. Kuzmina, E. pachanov, Y. Shachbazian, A.M. Prieur, V. Artamonova, R. Joss, F. Zulian, R. Schwartz, A. Buoncompagni, W. Emminger, I. Foeldvari, F. Falcini, E. Baildam, A. Martini. A randomized trial of two dose regimen of meloxicam compared to naproxen oral suspension in juvenile idiopathic arthritis. Pediatric Rheumatology Online Journal 2003, 1 (Vol 3): Abstract 44.
  42. I Foeldvari, A. Wierk. Vioxx? as an effective alternative for treatment of patients with juvenile idiopathic arthritis with side effects under other nonsteroidal drugs. Results of a therapeutic observation. Pediatric Rheumatology Online Journal 2003, 1 (Vol 3): Abstract 43.
  43. I. Foeldvari, A. Wierk. Steroid induced osteoporosis in children with rheumatic diseases. Results of a pilot study. Pediatric Rheumatology Online Journal 2003, 1 (Vol 5): Abstract 142.
  44. I Foeldvari, A. Wierk. Vioxx? as an effective alternative for treatment of patients with juvenile idiopathic arthritis (JIA). Annals of Rheumatic Diseases. 2003, 62 (Supplement 1.): 494 – AB075
  45. N Ruperto, Prieur, Machado, Murray, Bae, Joos, Foeldvari et al. Health related quality (HRQOL) of life of patients with juvenile idiopathic arthritis. Clinical Experimental Rheumatology 2003, 21: 535
  46. I Foeldvari, A. Wierk.. Methotrexate is an effective treatment for juvenile idiopathic arthritis associated uveitis. Clinical Experimental Rheumatology 2003, 21: 540
  47. N. Ruperto, N. Kuzmina, E. Pachanov, Y. Shachbazian, R. Mouy, V. Artamonova, R.Joos, F. Zulian, R. Schwarz, A. Buoncompagni, W. Emminger, I.Foeldvari et al. A randomized trial of two dose regimen of meloxicam compared to naproxen oral suspension in juvenile idiopathic arthritis. Clinical Experimental Rheumatology 2003, 21: 542.
  48. I. Foeldvari, A. Wierk. Results of calcaneal ultrasound measurement to assess steroid induced osteoporosis. Clinical Experimental Rheumatology 2003, 21: 556.
  49. G. Horneff, H. Schmeling, I. Foeldvari et al: Drug survival and reasons for discontinuation of etanercept therapy in juvenile idiopathic arthritis. EULAR 2004 Berlin. Ann Rheum Dis 2004, 61 ( Suppl1): 383- FRI0468.
  50. I. Foeldvari, A. Wierk. Results of leflunomide (LEF) therapy in patients with juvenile idiopathic arthriris(JIA): a pilot noncontrolled therapeutic intervention. Clin Expr Rheumatol 2004, 22: 524.
  51. I. Foeldvari, A. Wierk. Healthy children have a significantly increased skin score asessed with the modified Rodnan Skin Score. ACR 2004. Artthritis Rheum 2004, 50 ( Suppl): S 419, A 1045.
  52. G. Horneff, H. Schmeling, D. Moebius, I. Foeldvari. Efficacy of etanercept in active refractory juvenile spondyloarthropathy. Prospective open study of 40 patients. ACR 2004. Artthritis Rheum 2004, 50 ( Suppl): S 91, A 74.
  53. I. Foeldvar, A. Wierk. Characteristics of patients with temporomandibular joint involvement associated to juvenile idiopathic arthritis. 33% of the patients are asymptomatic despite signs of active arthritis in imaging studies. EULAR 2005 , Ann Rheum Dis 2005, 64 – Supplement III: 509- SAT 0317.
  54. I. Foeldvari, J. Kümmerle-Deschner, G. Horneff. A. Oliviere, C. le Blanc, M. Fischbach, Stella Garay, M. Hendrickson, M.M. Katsikas, K. O´Neill, J.P. Whelan, A. Wierk, T. Saurenmann. Results of a multinational survey regarding the use of tumor necrosis factor alfa blocker in the treatment of juvenile idiopathic arthritis associated severe uveitis. EULAR 2005, Ann Rheum Dis 2005, 64 – Supplement III: 509- SAT 0315.
  55. G. Martini, F. Vittadello, B.H. Athreya, T.A. Lehman, I. Foeldvari, R. Russo, A. Eberhard, R. Cuttica, A. Ravelii, S.F.K. De Oliveira, G. Susic, G.A. Lysina, D. Nemcova, S. Nielsen, F. Falcini, R. Sundel, H. Girschick, A.P. Lotito, S. Al-Mayouf, I. Orban, R. Ten Cate, F. Zulian. Mortality in juvenile systemic sclerosis (jSS): Daa from the Padua international database of 153 patients. XII. European Pediatric Rheumatology Congress, Versaille, Frankreich 2005. Clinical Exp Rheumatol 2005; 23 (Suppl 37): S-42.
  56. I. Foeldvari, A. Wierk. Results of the multinational survey regarding the use of tumor necrosis factor alfa blocker in the treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agent. XII. European Pediatric Rheumatology Congress, Versaille, Frankreich 2005. Clinical Exp Rheumatol 2005; 23 (Suppl 37): S-63.
  57. G. Martini, F. Vittadello, B.H. Atheya, T. Lehman, I. Foeldvari, R. Russo, A. Eberhard, R. Cuttica, A. Ravelli, G. Susic, R. Sundel, F. Falcini, H. Girschick, AP. Lotito, S. Al-Mayouf, I. Orban, R. TenCate, F. Zulian for PRES. Mortality in juvenile systemic sclerosis : data from the Padua international database of 153 patients. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1412.
  58. F. Zulian, P. Woo, B.H. Athreya, R.M. Laxer, T.A. Medsger, T.A. Lehman, M. Matucci-Cerinic, G. Martini, A. Ravelli, R. Russo, R. Cuttica, S.F.K. de Olivieri, C. Denton, I. Foeldvari, N. Ruperto. Preliminary classification criteria for systemic sclerosis in children. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1413.
  59. I. Foeldvari, J. Kümmerl-Deschner, S. Nielson, G. espada, G. Horneff, B. Bica, A.N. Olivieri, C. leBlanc, M. Fischbach, S. Garay, M. Henrickson, M. Katsikas, K. O´Neill, P.J. Whelan, A. Wierk, T. Saurenmann. Tumor necrosis factor alfa blocke rare effective in the treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: results of the multinational survey. 2005 Annual Scientific Meeting of the American College or Rheumatology, San Diego, Ca., USA. Arthritis Rheum 2005, 52 (Suppl): A 1416.
  60. I. Foeldvari, S.Nielson, N.Tzaribachev,J.Quitsch,F. Dressleer, M. Hilario, R. Küster, M. Borte, H. Mazur-Zielinska, E. Jäger-Roman, A. Wierk. Results of a multinational survey regarding the use of cyclosporine A in the treatment of juvenile idiopathic arthritis associated uveitis. Ann Rheum Dis 2006, 65 Suppl II: 251 – THU0448
  61. I. Foeldvari, J. Anton, J. Chaitow, J. davidson, G. Higgins, T. Lehman, C. Len, A. Reiff, R. Russo, F. Zulian. Development of a minimal standard fort he evaluation of patients with juvenile systemic sclerosis. Ann Rheum Dis 2006, 65 Suppl II: 251 – THU0449
  62. G. Horneff, D. Moebius, H. Michels, I. Foeldvari. Etanercept and leflunomide combination therapy in juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65 Suppl II: 445 – FRI0515
  63. K.Minden, M.Neiwerth, A. Heiligenhaus, I. Foeldvari, G. Ganser, A. Zink. Extraarticular manifestation in juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65 Suppl II: 445 – FRI0532
  64. K.Minden, M.Neiwerth, I. Foeldvari, G. Ganser, A. Zink. Prevalence of being overweight among children and adolescent with juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65 Suppl II: 445 – FRI0544
  65. I. Foeldvari, A. Wierk, D. Endres, K. Grünberg. Splints are an effective treatment for flexion contractres of the knee associated to juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65 Suppl II: 646- AB0442.
  66. A. Wierk, I. Foeldvari: Befragung von Kindern und Jugendlichen über die Akzeptanz und Probleme bei der Verwendung von Methotrexat in der Kinder- und Jugendrheumatologie. Kinder- und Jugendmedizin 2006, 6: A 47, Abstract 31.
  67. I. Foeldvari, J. Anton, J. Davidosn, G. Higgins, T. Lehman, C. len, R. Russo, F. Zulian: Entwicklung eines Minimal-Standards zur Evaluation von Patienten mit juveniler Systemischer Sklerodermie. Kinder- und Jugendmedizin 2006, 6: A 51, Abstract 51.
  68. I. Foelvari, J. Anto, J. Chaitow, J. Davidson et al. Development of a minimal standard for he evaluation of patients with juvenile systemic sclerosis. Arthritis Rheum 2006,54 (Suppl): S 683, A 1708
  69. I. Foeldvari , A. Heiligenhaus, S. Nielsen, N. Tzaribachev, et al. Results of a multinational survey regarding the use of Cyclosporin A in the treatment of juvenile idiopathic arthritis associated uveitis. Arthritis Rheum 2006,54 (Suppl): S 683, A 1709
  70. I. Foeldvari, I.S. Szer, L.S. Zemel, M. Liu-Dumaw, B.J. Bloom. Report if a 12 week study of celecoxib vs Naproxen in children with juvenile rheumatoid arthritis. Arthritis Rheum 2006,54 (Suppl): S 683, A 171.
  71. F. Zulian, T Avcin, I. Foeldvari, G. Martini, F. Vitadello, C. Wouters. The juvenile scleroderma international (JUSI) database. An instrument for improving research and standard of care in a rare disease in childhood. THU0337, EULAR 2007, Barcelona.
  72. N. Ruperto, D.J. Loevell, S. Goodamn, A. Reiff, L. Jung, K. Jarosova, C. Sandborg, I. Foeldvari, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body surfa e area dosing to fixed-dosing in the open-label extension (OLE) of a phase III. study. THU0196 EULAR 2007, Barcelona.
  73. I. Foeldvari, S. Nielsen, J. Anton-Lopez, G. Reuter, L. Hoppenrijs, B. Fiebig et. al. Methotrexate is an effective treatment option for juvenile idiopathic arthritis assoiciated uveitis. SAT0393, EULAR 2007, Barcelona.
  74. I. Foeldvari, A. Wierk. Leflunomide is an effective alternative in the treatment for patient with juvenile idiopathic arthritis. SAT0394, EULAR 2007, Barcelona.
  75. I Foeldvari, S Nielsen, J Anton, G Reutter, L Hoppenrijs, B Fiebig, N Tzaribachew, J Walsh, A Wierk. Methotrexyte is an effective treatment option for juvenile idiopathic arthritis associated uveitis. Poster 28, page 130, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  76. C Mallattia, G Filocarmo, I Foeldvari, H Michels, C Pruunsild, S Nielsen et al. Identification of 254 famileis with juvenile idiopathic arthritis affected sibpairs: results of the PRINTO survey. Poster 67, page 174, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  77. N Ruperto, DJ Lowell, S Goodman, A Reiff, L Jung, K Jarosoa, I Foeldvari, J Rovensky, K Minden, R vehe, GH Horneff, M McIlraith, J Medich, A martini, EH Giannini. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body surface dosing to fixed dosing. Poster 69, page 176, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  78. I Foeldvari, A Wierk. Most patients have an atypical presentation for familiar Mediterranean fever. Poster 139, page 255, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  79. F Zulian, T Avcinb, I Foeldvari, G Martini, F Vittadello, C Wouters. The juvenile scleroderma international (JUSI) database: an instument for improving research and standard of care in a rare disease in childhood. Poster 269, page 397, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  80. I. Foeldvari, J Anton, J Chaitow, E Baildam, G Higggins, T Lehman, C len, A Reiff, R Russo, F Zulian. Development of a minimal standard for the evaluation of patients with juvenile systemic sclerosis in a prospective inception cohort. Poster 270, page 398, Abstract book of the 14 th European Pediatric Rheumatology Congress, Istanbul, Turkey. 2007.
  81. I Foeldvari, A Tyndall, F. Zulian, U. Mueller-Ladner, L. Czirjak, O. Kowal-Bielecka, D. Farge Bancel, M Matucci-Cerinic for the EUSTAR group. Similar outcome and organ involvement pattern of patients with juvenile and young adult onset systemic sclerosis. Data from the Eular Database. ACR 2007, Boston. Arthritis Rheum 2007, 56 (Suppl): A 1, S 53.
  82. I Foeldvari, G Ganser, J Roth, R Trauzeddel, D Moebius, A Thon, R Haefner, K Mathony, A Wierk, G Horneff fort he members of the German Etanercept Registry. Etanecept is an effective therapeutic option for children with juvenile idiopathic enthesitis related arthritis- Results from the German Etanercept Registry. ACR 2007, Boston. Arthritis Rheum 2007, 56 (Suppl): A 225, S 135.
  83. D Lowell, N. Ruperto, S Goodman, A Reiff, L Jung, K Jarosova, C Sandborg, I Foeldvari et al. Adalimumab fort h treatment of patients with juvenile rheumatoid arthritis: Safety and efficacy after conversion from body surface area dosing to weight-based fixed dosing. ACR 2007, Boston. Arthritis Rheum 2007, 56 (Suppl): A895, S 373.
  84. G Honeff, I Foeldvari, G Ganser, H Michels, H Girscick, RM Kuester, A Thon. Growth reconstitution in juvenile idiopathic arthritis (JIA) upon treatment with etanercept is related to clinical improvement and gender. ACR 2007, Boston. Arthritis Rheum 2007, 56 (Suppl): A 900, S 375.
  85. O Kowal-Bielecka, R Landewe, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C denton, D Farge, K Fliegelstone, I Foeldvari et al. EULAR/EUSTAR Recommendation for the treatment of systemic sclerosis. ACR 2007, Boston. Arthritis Rheum 2007, 56 (Suppl): A 30, S 64.
  86. I. Foeldvari, J. Anton, K. Minden, S. Nielsen, R.K. Sauerenmann, V. Strand, A. Heiligenhaus. Proposal for outcome measures for juvenile idiopathic arthritis related uveitis – from the JIA-Uveitis- Outcome Working Group. EULAR 2009, Copenhagen, FRI 0448. Ann Rheum Dis , 2009, Suppl.
  87. I. Foeldvari, T. Avcin, K. Minden, C. Len, J. Anton, J. Chaitow, E. Baildam, G. Higgins, T. Lehman, S. Maillard, A. Reiff, R. Russo, F. Zulian, A. Wierk. Report form the recruitement process fort he juvenile systemic sclerosis inceptions cohorte. www.juvenile-scleroderma.com. EULAR 2009 Copenhagen, Denmark. Ann Rheum Dis 2009, 68, Suppl.
  88. I. Foeldvari, B. Bica, F. Dedeoglu, A. Wierk. Efficacy of Rituximab in RF Factor negative juvenile idiopathic arthritis. FRI 0450EULAR 2009 Copenhagen, Denmark. Ann Rheum Dis 2009, 68, Suppl.
  89. A.F. Jansson, C. Sengler, J. Kümmerle-Deschner, B. Gruhn, B. Kranz, H. Lehmann, D. Kleinert, L. Pape, D. Möbius, J. Peitz, D. Föll, H.J. Girschick, I. Foeldvari, J.P. Haas, D. Haffner, V. Grote. B-cell depletion for autoinflammatory diseases in pediatric patients a retrospecitve study. THU 0390 EULAR 2009 Copenhagen, Denmark. Ann Rheum Dis 2009, 68, Suppl.
  90. I. Foeldvari, N. Helmus, A. Wierk. Validation of the proposed tool in Germany for early referral of children and adolescent with signs and symptomes suggestive of chronic arhtropathy to paediatric rheumatology centres. FRI 0449 EULAR 2009 Copenhagen, Denmark. Ann Rheum Dis 2009, 68, Suppl.
  91. Ivan Foeldvari, J. Anton, J. Deboer, C. Edelsten, , E. Graham, K. Kotaniemi, Heinola, Finland, F. Mackensen, , S. Nielsen, C. E. Rabinovich, K. Minden, R. K. Saurenmann, Justine A. Smith, A. Heiligenhaus. Proposal for outcome measures for juvenile idiopathic arthritis associated uveitis from the JIA Uveitis working group. ACR 2009 Philadelphie, USA. Arthritis Rheum 2009, 60 (Suppl): Abstract #257
  92. Minden K, Niewerth M, Weber K, Zink , Seipelt E, Foeldvari I, Girschick H, Horneff G. Long-term outcome of patients with juvenile idiopathic arthritis (JIA) treated with Etanercept-results of the biologic register JuMBO. ACR 2010.
  93. Dörte Huscher, Nicholas Roubinis, Jerome Avouac, Frank Behrens, Christopher P Denton, Daniel E Furst, Ivan Foeldvari, Marc Humbert, Otylia Kowal-Bielecka, Marco Matucci-Cerinic, Peter Nash, Christian F. Opitz, David Pittrow, Lewis J Rubin, James R Seibold, Marius M Hoeper, Mark F Morris, Simon A Teal, Oliver Distler on behalf of the EPOSS group. Validation of 6 minute walking distance in patients with pulmonary arterial hypertension associated with systemic sclerosis. ACR 2010.
  94. Gerd Horneff1, Gerd Ganser, Ivan Foeldvari, MD, Andreas Urban, Ariane Klein. Efficacy and Safety of Oral and Parenteral Methotrexate Therapy in Children with Juvenile Idiopathic Arthritis. ACR 2010
  95. Ivan Foeldvari, MD, Nina Thome, Gerd Horneff, MD. Methotrexate Gives Protection Against the New Onset of Uveitis in Combination with Etanercept. Data from the German Etanercept Registry. ACR 2010
  96. Ivan Foeldvari, MD, Angela Wierk, RN, Claudie Len, Maria Martha Katsicas, Avcin Tadey, Till Kallinich, Isabelll Kone-Paut, Kirsten Minden, Luc Mouthon, Juergen Brunner, Yuoef Uziel. Update on the Juvenile Systemic Sclerosis Inception Cohort. www.juvenilescleroderma.com.
  97. I Foeldvari, G.Himmelmann. Preliminary results for 6 min walk values in healthy German children. 2 nd Systemic Sclerosis World Congress, 02.-04.2012, Madrid . Spain. Rheumatology 2012, Volume 51, Supplement 2; PS217, ii96.

nach oben

Abstracts-Präsentationen:

  1. I. Foeldvari: A rare Lymphoma, Franklin Syndrome. International Meeting of Young Oncologists, Szeged, Hungary, April 1987.
  2. J. Dippel, I. Foeldvari: Therapy of juvenile chronic arthritis with polyarticular onset in relation to the detection of hidden IgM-rheumatoid factor. International Symposium on Pediatric Rheumatology, Paris, France, 1989.
  3. I. Foeldvari, F.J. Schulte: Familiar accumulation of C4 deficiency and antiphospholipid antibodies. 4th Prague International Paediatric Rheumatologic Symposium. Prague 1992.
  4. I. Foeldvari, R.G. Kopelman, J.C. Jacobs: Does complement deficiency predispose early age of onset of SLE? 4th Prague International Paediatric Rheumatologic Symposium. Prague 1992.
  5. I. Foeldvari, M. Bidde: Ergebnisse der Befragung der Eltern über ihren Weg zu der Sprechstunde bei der Erstvorstellung in der kinderrheumatologischen Ambulanz. Jahrestagung der Arbeitsgemeinschaft Kinder- und Jugendmedizin, Tübingen, Mai 2000.
  6. I. Foeldvari: Results of the multinational survey regarding a therapeutic study in juvenile systemic sclerosis. 6th International workshop on scleroderma research, Keble College Oxford, UK, 8/2000.
  7. L.Huck, K. Meyer, I. Foeldvari, B. Kahl-Nieke: Juvenile idiopathische Arthritis - Ein Fallbericht. Deutsche Gesellschaft für Kieferorthopädie, 74. Jahrestagung Friedrichshafen, 09/2001.
  8. K.Meyer, L. Huck, I. Foledvari, B. Kahl-Nieke: das Kiefergelenk bei juveniler idiopathischer Arthritis - Klinische Befunde und Diagnose. Deutsche Gesellschaft für Kieferothopädie, 75. Jahrestagung, Hamburg. 09/2002.
  9. I. Foeldvari, A. Wierk. Healthy children have a significantly increased skin score assessed with the modified Rodnan Skin Score. VIII. International Workshop on Scleroderma Research - 2004, Trinity College, Cambridge, UK.
  10. I Foeldvari, S Nihtyanova, A. Wierk, C Denton. Langzeitprognose von Patienten mit juveniler systemischer Sklerodermie. Ergbnisse us einen grossen monoznetrischen Kohorte. KR 14. DGRH Berlin 2008

nach oben

Hauptseite | Die Praxis | Dr. Ivan Foeldvari | Was ist Rheuma? | Die Elterninitiative | Kontakt | Impressum | Links